学术周报 · IF≥10 或专科旗舰刊
神经内科领域文献阅读汇编
2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Biosensors & bioelectronics | 7 | IF 11.8 |
| Neurology and therapy | 4 | IF 4.7 |
| Circulation | 4 | IF 41.3 |
| Science advances | 4 | IF 13.9 |
| European journal of preventive cardiology | 3 | IF 10.0 |
| Stroke | 3 | IF 11.1 |
| JAMA neurology | 3 | IF 23.6 |
| European heart journal | 3 | IF 45.3 |
| Ageing research reviews | 2 | IF 15.5 |
| Journal of the American Chemical Society | 2 | IF 16.6 |
1痴呆与认知障碍 (20篇)
临床研究 (8篇)
APOE ε4 is the strongest common genetic risk factor for late-onset Alzheimer's disease and is associated with age-related cognitive decline. Whether its association with cognition, and that of other candidate variants, is uniform across cognitive domains or domain-specific remains unclear. To synthesize single-variant candidate-gene evidence on domain-specific cognitive function (episodic memory, executive function, language, visuospatial function, attention, processing speed) in the Alzheimer's disease-indexed literature, beyond APOE alone. We searched PubMed, Embase, and Scopus on 18 June 2026 without date restriction (PRISMA 2020; PROSPERO CRD420261446003). Of 6,453 records, we included 111 studies; all search strings required an Alzheimer's disease term. We applied two risk-of-bias tools to every study. Two reviewers extracted and appraised data using AI assistance and verified them against the source text, without reporting agreement statistics. Synthesis was narrative by domain, with an exploratory effect-size meta-analysis for APOE. APOE was examined in 70 of 111 studies (63%), and 30 further genes were examined in two or more studies each. Detrimental APOE associations were most consistent for episodic memory (48 of 75 findings; sign test p=3.3×10⁻⁹) and executive function (28 of 54; p=5.1×10⁻⁴). The direction of association did not differ between domains (χ²(5)=2.13, p=0.83; 84% detrimental), but detection frequency did (null results 28% to 65%; χ²(5)=20.16, p=0.001). In an exploratory meta-analysis of 36 studies, pooled ε4 effects on performance were small and negative in all six domains, significantly so only for episodic memory (Hedges' g=-0.14, 95% CI -0.21 to -0.07; executive function -0.07, -0.13 to 0.00), and within the same studies the episodic memory effect exceeded the executive function and language effects. The episodic memory result was robust to square-root sample-size weighting, age restriction and significance-threshold re-analysis; the executive function result was less robust, and the two risk-of-bias tools disagreed on whether either survives quality stratification. The direction of APOE's association with cognition appears uniform across domains; it is detected most often on episodic memory measures, where its standardized effect also exceeds that on executive function and language measures, and part of the between-domain variation in detection, and possibly in effect size, may reflect the instruments used. Evidence beyond APOE is fragmented, with 93 of 123 non-APOE genes (76%) supported by a single study. Single-variant evidence from the Alzheimer's disease literature thus converges on APOE, with only preliminary evidence for a few other Alzheimer's disease risk loci, in contrast to the highly polygenic architecture that genome-wide studies describe for general cognitive function.
中文摘要:APOE ε4是晚发型阿尔茨海默病最强的常见遗传风险因素,且与年龄相关的认知衰退有关。其在不同认知领域或特定领域的认知关联是否一致,以及其他候选变异的关联情况尚不明确。为综合除APOE外关于阿尔茨海默病索引文献中特定认知功能(情景记忆、执行功能、语言、视空间功能、注意力、处理速度)的单基因候选证据,我们于2026年6月18日检索了PubMed、Embase和Scopus数据库,无日期限制(遵循PRISMA 2020;PROSPERO注册号CRD420261446003)。在6453条记录中,纳入111项研究,所有搜索词均要求包含阿尔茨海默病术语。我们对每项研究应用了两个偏倚风险评估工具。两位审稿人利用人工智能辅助提取和评估数据,并与源文本进行核对,未报告一致性统计量。按领域进行叙述性综合,并对APOE进行了探索性效应量荟萃分析。在111项研究中,70项(63%)考察了APOE,另有30个基因在两项或更多研究中被考察。APOE的有害关联在情景记忆(75项发现中的48项;符号检验p=3.3×10⁻⁹)和执行功能(54项中的28项;p=5.1×10⁻⁴)中最为一致。领域间的关联方向无差异(χ²(5)=2.13,p=0.83;84%为有害),但检测频率存在差异(零结果占28%至65%;χ²(5)=20.16,p=0.001)。在36项研究的探索性荟萃分析中,汇总的ε4对各项表现的影响均为小而负,仅在情景记忆方面显著(Hedges' g=-0.14,95% CI -0.21至-0.07;执行功能为-0.07,-0.13至0.00),且在相同研究中,情景记忆效应超过了执行功能和语言效应。情景记忆结果对平方根样本量加权、年龄限制和显著性阈值重新分析具有稳健性;执行功能结果稳健性较差,且两项偏倚风险评估工具在是否通过质量分层方面存在分歧。APOE与认知的关联方向在各领域似乎是一致的;其在情景记忆测量中检测频率最高,其标准化效应也超过执行功能和语言测量,而检测间的领域间变异以及可能的效应量差异可能反映了所用仪器的影响。除APOE外的证据支离破碎,123个非APOE基因中有93个(76%)仅由一项研究支持。因此,来自阿尔茨海默病文献的单基因证据集中于APOE,仅有少数其他阿尔茨海默病风险位点的初步证据,这与全基因组研究描述的普遍认知功能的高度多基因架构形成对比。
Alterations in metabolism, stress response, sleep, circadian rhythms and neuroendocrine processes are key features of ageing and neurodegeneration1,2. These fundamental processes are regulated by the hypothalamus, yet how its functionally distinct subregions and cell types change during human ageing and Alzheimer's disease (AD) remains largely unexplored. Here we present HypoAD, an atlas of the human hypothalamus in ageing and AD, including high-resolution magnetic resonance imaging from 458 individuals and single-nucleus RNA sequencing of 614,403 nuclei from young participants, patients with AD and age-matched non-dementia control participants. We show that hypothalamic subregions governing metabolism, stress and circadian rhythms are particularly vulnerable, showing notable changes in both volumes and gene expression during ageing and AD. At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD. These signatures were reflected in specific cell types: microglia transitioned to a pro-inflammatory state, whereas inhibitory neurons within sleep-regulating and circadian-regulating hypothalamic subregions showed the most profound transcriptional alterations, including disruptions in ligand-receptor interactions and G-protein-coupled receptor signalling. HypoAD provides a high-resolution volumetric map and a transcriptomic atlas of the human hypothalamus in ageing and AD, relating lifestyle and behavioural changes to the relevant volumetric and molecular pathways. In addition, HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression.
中文摘要:代谢、应激反应、睡眠、昼夜节律及神经内分泌过程的改变是衰老和神经退行性变的关键特征。下丘脑调控这些基本过程,但其功能不同的亚区及细胞类型在人类衰老和阿尔茨海默病(AD)中的变化仍 largely 未明。本研究提出 HypoAD,这是一个涵盖人类衰老和 AD 的下丘脑图谱,包含来自 458 名个体的高分辨率磁共振成像数据,以及来自年轻参与者、AD 患者和年龄匹配的非痴呆对照参与者的 614,403 个细胞核的单细胞核 RNA 测序数据。我们表明,调控代谢、应激和昼夜节律的下丘脑亚区特别脆弱,在衰老和 AD 期间体积和基因表达均发生显著变化。在分子水平上,机器学习模型识别出炎症反应和昼夜节律调节因子是 AD 的关键细胞预测指标。这些特征反映在特定细胞类型中:小胶质细胞转变为促炎状态,而睡眠调节和下丘脑昼夜节律调节亚区内的抑制性神经元表现出最深刻的转录改变,包括配体-受体相互作用和 G 蛋白偶联受体信号传导的破坏。HypoAD 提供了人类衰老和 AD 下丘脑的高分辨率体积图和转录组图谱,将生活方式和行为变化与相关的体积及分子通路联系起来。此外,HypoAD 为研究下丘脑功能障碍提供了框架,并建立了旨在减轻生理紊乱以潜在延缓疾病进展的目标干预路线图。
Plasma biomarkers for Alzheimer's disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ42/Aβ40 and p-tau181/Aβ42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic (n = 129), a primary care (n = 220) and a research cohort (n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83-91%) and p-tau217/Aβ42 (83-92%) had comparable accuracies to CSF (88-90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90-97%) remained comparable to CSF (91%) in the clinical cohorts (all Padj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.
中文摘要:全自动平台上的阿尔茨海默病血浆生物标志物提供了便捷且具成本效益的诊断工具。本研究旨在比较Lumipulse平台的血浆磷酸化tau217(p-tau217)及p-tau217/β-淀粉样蛋白42比值(p-tau217/Aβ42)与监管批准的脑脊液(CSF)生物标志物(Aβ42/Aβ40和p-tau181/Aβ42),以在记忆门诊队列(n=129)、初级保健队列(n=220)和研究队列(n=165)中识别阿尔茨海默病病理(基于Aβ-PET视觉判读)。血浆和CSF生物标志物均采用了监管批准的截断值。血浆生物标志物识别Aβ病理的曲线下面积介于0.90至0.96之间。使用单一截断值时,在所有队列中,血浆p-tau217(83-91%)和p-tau217/Aβ42(83-92%)的准确性与CSF(88-90%)相当(所有P≥0.05)。采用双截断值方法时,血浆p-tau217(90-97%)在临床队列中仍与CSF(91%)相当(所有Padj≥0.12)。结果还提供了基于队列推导的截断值。总之,监管批准的血浆p-tau217和p-tau217/Aβ42在检测有症状个体的Aβ病理方面,表现出与监管批准的CSF检测相当的效能。
Patients are increasingly learning Alzheimer disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient knowledge and psychological well-being. To determine whether a digital platform is comparable to clinician-mediated telehealth sessions for returning apolipoprotein E (APOE) genotype and plasma phosphorylated tau 217 (p-tau217) results on outcomes of knowledge and psychological well-being. The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a digital platform compared to clinician-mediated return of APOE genotype and optional p-tau217 results. Enrollment was conducted October 2024 through February 2025. Follow-up was completed November 2025. This was a decentralized, fully remote trial taking place across the contiguous US. Eligible participants were aged 60 to 80 years and had previously undergone APOE genotyping (without disclosure) via GeneMatch, passed psychological screening, had internet access, and could speak English. Of the 13 033 people invited by GeneMatch, 2052 accepted, and 813 were assessed for eligibility. Of 666 randomized, 651 were ultimately included. Participants were randomized, 2:1, to the eSMARTER digital platform or study clinician-mediated return of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional p-tau217 disclosure via the same randomized modality. Primary outcomes at 1 to 7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori noninferiority margins. A total of 674 persons were eligible and provided demographic information. Of these, 651 participants had been randomized to study clinician-mediated (n = 216) or digital disclosure (n = 435) and completed APOE disclosure (mean [SD] age, 68 [4.7] years; 439 [67%] female; mean [SD] telephone Montreal Cognitive Assessment score, 19 [2]; 66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, and 208 [32%] noncarriers) A total of 604 participants completed the study; 500 completed optional p-tau217 disclosure. Baseline characteristics were balanced across groups. At 1 to 7 days following APOE disclosure, scores on AD-related knowledge, Patient-Reported Outcomes Measurement Information System Anxiety T-score, and disease-specific distress measures met noninferiority. Return of APOE genotype by the eSMARTER digital platform is noninferior to study clinician-mediated telehealth disclosure. No significant between-group differences were found following return of p-tau217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results. ClinicalTrials.gov Identifier: NCT06459583.
中文摘要:数字化传递载脂蛋白E基因型与磷酸化tau 217结果:eSMARTER随机临床试验。患者正越来越多地通过电子健康门户获知阿尔茨海默病(AD)遗传和生物标志物结果。需要评估用于返回AD风险信息的替代可扩展传递模式,以最佳支持患者知识和心理健康。旨在确定数字平台在返回载脂蛋白E(APOE)基因型和血浆磷酸化tau 217(p-tau217)结果方面,在知识和心理健康结局上是否与临床医生介导的远程医疗会话相当。风险检测教育与结果返回自我介导替代方案评估(eSMARTER)研究是一项非劣效性试验,比较数字平台与临床医生介导返回APOE基因型及可选p-tau217结果。入组于2024年10月至2025年2月进行。随访于2025年11月完成。这是一项在美国本土连续地区开展的去中心化、完全远程试验。合格参与者年龄为60至80岁,既往通过GeneMatch接受过APOE基因分型(未告知结果),通过心理筛查,具备互联网接入,并能说英语。GeneMatch邀请的13 033人中,2052人接受邀请,813人接受了资格评估。666名随机分配者中,651名最终被纳入。参与者按2:1随机分配至eSMARTER数字平台或研究临床医生介导的APOE基因型返回。在APOE披露后6个月评估之后,参与者通过相同的随机分配方式获得可选p-tau217披露。APOE披露后1至7天的主要结局包括焦虑、疾病特异性困扰和AD相关知识的变化,均在预先设定的非劣效性界值内。共有674人符合条件并提供人口学信息。其中,651名参与者被随机分配至研究临床医生介导披露组(n=216)或数字披露组(n=435),并完成了APOE披露(平均[SD]年龄为68[4.7]岁;439[67%]为女性;平均[SD]电话蒙特利尔认知评估评分为19[2];66[10%]为APOE4纯合子,377[58%]为杂合子,208[32%]为非携带者)。共有604名参与者完成研究;500名完成了可选p-tau217披露。基线特征在组间均衡。APOE披露后1至7天,AD相关知识、患者报告结局测量信息系统焦虑T评分以及疾病特异性困扰测量的评分均达到非劣效性。eSMARTER数字平台返回APOE基因型不劣于研究临床医生介导的远程医疗披露。p-tau217结果返回后未发现显著的组间差异。这些结果共同提示,该数字平台可能为返回AD遗传和生物标志物结果提供一种基于证据的可扩展方法。ClinicalTrials.gov注册号:NCT06459583。
The risk of developing dementia at any given age has fallen steadily in Europe and the United States over recent decades. A key unresolved question is whether recent generations reach older age with better cognitive capacity, experience slower cognitive decline, or both, as this has implications for when preventive interventions are likely to have the greatest impact. Analyzing ~783,000 episodic-memory assessments from ~219,000 individuals in five longitudinal studies followed for up to 30 years, we find that later-born generations benefit from a double dividend, with higher memory levels entering old age and slower decline thereafter. The combined advantage is large enough to plausibly account for the reported 13% per-decade decline in dementia incidence. Improvements are concentrated among the fastest decliners; later-born generations show longer periods of stable memory, and their slower decline is mirrored by lower rates of clinical impairment and slower hippocampal atrophy. Calendar-time trends affecting all generations simultaneously are unlikely to explain these differences. Because memory level is built mainly in early life whereas the rate of decline is shaped by conditions in adulthood, sustaining the decline in dementia incidence will require prevention policies that protect brain health across the whole lifespan, beginning in childhood.
中文摘要:近几十年来,欧洲和美国各年龄段患痴呆症的风险持续下降。一个关键未解问题是,较晚出生的世代是否以更好的认知能力进入老年期、经历更缓慢的认知衰退,或两者兼有,因为这关系到预防性干预措施何时可能产生最大影响。我们分析了五项纵向研究中约21.9万名个体进行的约78.3万次情景记忆评估数据,随访时间长达30年,发现晚出生世代受益于双重红利,即进入老年期时记忆水平更高,此后衰退更慢。这种综合优势之大,足以合理解释报告的痴呆症发病率每十年下降13%的现象。改善主要集中在衰退最快的群体中;晚出生世代表现出更长的稳定记忆期,其较慢的衰退也反映在较低的临床损伤率和较慢的海马体萎缩率上。同时影响所有世代的日历时间趋势不太可能解释这些差异。由于记忆水平主要在生命早期建立,而衰退速率由成年期的状况塑造,因此要维持痴呆症发病率的下降,需要制定保护全生命周期大脑健康的预防政策,从儿童时期开始实施。
Alzheimer disease (AD) pathology can be detected years before symptom onset, but some individuals who are biomarker positive and cognitively unimpaired (CU) remain asymptomatic. To estimate 5- and 10-year absolute risks of mild cognitive impairment (MCI) and dementia using continuous plasma phosphorylated tau 217 (p-tau217) and p-tau217/amyloid β 42 (Aβ42). This cohort study included participants from the Mayo Clinic Study of Aging (MCSA) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants were CU individuals aged 60 to 90 years with baseline Fujirebio Lumipulse plasma p-tau217 measurements, APOE genotyping, and longitudinal clinical follow-up. The MCSA is a population-based longitudinal cohort of residents in Olmsted County, Minnesota; ADNI is a multicenter observational cohort. MCSA data were ascertained from October 2008 to September 2025; ADNI data from September 2005 to January 2026. Age, sex, APOE ε4, p-tau217, and p-tau217/Aβ42. Transition from CU to MCI and dementia estimated using continuous-time multistate models. In the MCSA cohort (n = 1644), the median (IQR) age was 72 (66-79) years; 804 participants (49%) were female and 840 (51%) were male. In the ADNI cohort (n = 534), the median (IQR) age was 72 (68-77) years; 297 participants (56%) were female and 237 (44%) were male. A p-tau217 of 0.324 pg/mL vs 0.072 pg/mL (90th vs 10th percentile) was associated with 2.66 (95% CI, 2.02-3.51), 3.02 (95% CI, 2.21-4.12), 2.62 (95% CI, 1.99-3.46), and 2.79 (95% CI, 2.04-3.81) greater hazard of clinical progression in MCSA female participants who did not carry the APOE ε4 variant (ε4-), females who did carry the APOE ε4 variant (ε4+), males who were ε4-, and males who were ε4+, respectively. In ADNI, hazards were 2.67 (95% CI, 1.86-3.85), 2.83 (95% CI, 1.89-4.22), 2.08 (95% CI, 1.48-2.92), and 3.99 (95% CI, 2.59-6.13), respectively. In MCSA, higher baseline p-tau217 and older age were associated with greater absolute risk of progression. At age 75 years and assuming sex and APOE are at the MCSA means of 0.511 and 0.268, 5-year absolute risk of MCI increased from 7% (95% CI, 5%-8%) to 17% (95% CI, 13%-20%) for a p-tau217 concentration of 0.072 vs 0.324 pg/mL; 10-year absolute risk of MCI increased from 15% (95% CI, 12%-18%) to 35% (95% CI, 29%-41%; P < .001 for both). At 0.324 pg/mL, 5-year MCI risk increased from 6% (95% CI, 4%-8%) to 37% (95% CI, 32%-43%) for ages 65 to 85 years; 10-year risks were 17% (95% CI, 12%-21%) and 66% (95% CI, 57%-74%; P < .001 for both). Results were similar for p-tau217/Aβ42. This study found that higher plasma p-tau217 and older age were associated with higher 5- and 10-year risk of cognitive impairment. Plasma p-tau217 concentrations, combined with age, sex, and APOE ε4 status, can enable individualized estimation of short-term absolute risk of cognitive impairment in CU individuals, with applications in prognosis and trial enrichment in preclinical AD.
中文摘要:阿尔茨海默病病理可在症状出现前数年被检测到,但部分生物标志物阳性且认知功能正常的人群仍保持无症状状态。本研究旨在利用连续血浆磷酸化Tau217及p-tau217/淀粉样蛋白β42比值估算轻度认知障碍和痴呆的5年与10年绝对风险。该队列研究纳入来自明尼苏达州奥姆斯特德县居民的人口纵向队列MCSA以及多中心观察性队列ADNI的参与者。入选者为60至90岁、基线具有Fujirebio Lumipulse血浆p-tau217检测数据、APOE基因分型及纵向临床随访的认知功能正常个体。MCSA数据收集时间为2008年10月至2025年9月,ADNI数据为2005年9月至2026年1月。研究指标包括年龄、性别、APOE ε4、p-tau217及p-tau217/Aβ42比值,采用连续时间多状态模型估算从认知正常向轻度认知障碍和痴呆的转化风险。MCSA队列共1644人,中位年龄72岁,女性804人男性840人;ADNI队列共534人,中位年龄72岁,女性297人男性237人。在MCSA队列中,相较于第10百分位数的p-tau217水平0.072 pg/mL,第90百分位数的0.324 pg/mL与未携带APOE ε4变异的女性、携带该变异的女性、未携带该变异的男性以及携带该变异的男性的临床进展风险分别增加2.66倍、3.02倍、2.62倍和2.79倍。ADNI队列中相应风险倍数分别为2.67倍、2.83倍、2.08倍和3.99倍。在MCSA队列中,较高的基线p-tau217水平和较高年龄与更高的进展绝对风险相关。假设性别和APOE处于MCSA均值水平,在75岁年龄时,p-tau217浓度从0.072 pg/mL升至0.324 pg/mL时,轻度认知障碍的5年绝对风险从7%增至17%,10年风险从15%增至35%。在p-tau217为0.324 pg/mL时,年龄从65岁增至85岁时,5年轻度认知障碍风险从6%增至37%,10年风险从17%增至66%。p-tau217/Aβ42比值结果相似。研究表明较高血浆p-tau217和较高年龄与较高的5年和10年认知障碍风险相关。结合年龄、性别和APOE ε4状态的血浆p-tau217浓度可用于认知正常个体短期绝对认知风险的个体化估算,应用于前临床阿尔茨海默病的预后评估及试验富集。
Cardiovascular (CV) diseases and dementia share common risk factors and often coexist in older adults. Understanding the CV-brain interaction is essential for tackling their interconnected burden. This study investigated the link between CV phenotypes, brain architecture, and cognition. Overall, 15 519 UK Biobank participants without neurodegenerative diseases or stroke (median age 64 years, 49% female) were analysed. Confirmatory factor analysis aggregated 18 CV magnetic resonance imaging (MRI) biomarkers into latent variables for left ventricular systolic function (gSyst), diastolic (gDiast) function, and geometry (gGeom); arterial compliance was measured by aortic distensibility (AoD). Multivariable linear regression models evaluated associations with brain MRI phenotypes, including grey matter volume, white matter hyperintensities, MRI diffusion white matter microstructure, and hippocampal volume. Models were adjusted for age, body mass index, height, mean blood pressure, and CV risk factors. Exploratory mediation models evaluated whether hippocampal volume accounted for associations between CV phenotypes and cognition. gGeom, reflecting greater myocardial mass, wall thickness, and ventricular volumes, showed the strongest association with hippocampal volume [β = 0.082 (0.048-0.117) in females; β = 0.039 (0.006-0.071) in males] and was the only CV phenotype associated with better cognition, including higher fluid intelligence and faster reaction time. Hippocampal volume significantly accounted for the positive relationship between gGeom and cognition across sexes. In contrast, gSyst, gDiast, and AoD demonstrated weaker and less consistent associations with brain structure and were unrelated to cognition. Ventricular geometry emerged as the CV phenotype most strongly associated with brain architecture and cognition. Hippocampal volume may help explain this association, but further studies are needed to investigate causality.
中文摘要:心血管疾病与痴呆共享共同的风险因素且在老年人群中常共存。理解心血管与大脑之间的相互作用对于应对其相互关联的疾病负担至关重要。本研究探讨了心血管表型、大脑结构与认知之间的联系。研究分析了15519名无神经退行性疾病或卒中病史的英国生物银行参与者(中位年龄64岁,女性占49%)。通过验证性因子分析将18项心血管磁共振成像生物标志物聚合为左心室收缩功能、舒张功能和几何结构的潜在变量;动脉顺应性通过主动脉顺应性进行测量。多变量线性回归模型评估了这些指标与大脑磁共振成像表型(包括灰质体积、白质高信号、磁共振扩散白质微结构和海马体积)的关联,并调整了年龄、体重指数、身高、平均血压及心血管风险因素。探索性中介模型评估了海马体积是否介导了心血管表型与认知之间的关联。反映心肌质量、室壁厚度和心室容积增加的心血管几何结构指标与海马体积表现出最强的关联,且是唯一与更好认知功能(包括更高的流体智力和更快的反应时间)相关的心血管表型。跨性别分析显示,海马体积显著介导了心血管几何结构与认知之间正相关的关系。相比之下,左心室收缩功能、舒张功能和主动脉顺应性与大脑结构及认知的关联较弱且不一致。心室几何结构成为与大脑结构和认知关联最强烈的心血管表型。海马体积可能有助于解释这一关联,但需要进一步研究以探讨因果关系。
Digital wearable devices provide objective characterization of human behaviors in real-world settings, yet their implications for health and diseases remain incompletely understood. Here, we analyzed a large-scale accelerometry-based cohort, including 70,473 participants with up to 10 years of follow-up, yielding a total of 11.8 million person-hours of data. From this cohort, we constructed a comprehensive atlas of 210 accelerometer-derived phenotypes (ADPs), encompassing physical activity, sedentary behavior, sleep, circadian rhythm, step counts, and step intensity. The study identified 8149 ADP-disease and 36,614 ADP-trait associations across 406 diseases and 956 health-related traits. Step intensity and circadian rhythm emerged as the most prominent ADP domains associated with diseases. In addition, we developed an artificial intelligence (AI) framework, named Wearable-Accelerometry-based Temporal-Structural Network (WATSNet), achieving high discrimination (AUC >0.7) for 112 (28.1%) incident and 65 (34.0%) prevalent diseases, e.g., incidence of Parkinson's disease (AUC = 0.873) and dementia (AUC = 0.841). We provided evidence-informed behavioral benchmarks associated with lower disease risks: at least 0.8 h per day of moderate-to-vigorous physical activity, 10,000 daily steps, and 7.8 h of sleep per day. Furthermore, we evaluated the generalizability of both ADP-disease associations and the performance of WATSNet in an external dataset (n = 4406). Together, these findings provide a comprehensive landscape linking digital behaviors to diverse health outcomes (https://digital-phenome-atlas.com) and a foundation for precision health monitoring.
中文摘要:数字可穿戴设备能够提供真实世界环境中人类行为的客观特征描述,然而其对健康和疾病的影响尚不完全清楚。本研究分析了一个基于加速度计的大规模队列,包含70473名参与者,随访时间长达10年,共获得1180万人时的数据。基于该队列,我们构建了包含210个加速度计衍生表型(ADP)的综合图谱,涵盖身体活动、久坐行为、睡眠、昼夜节律、步数和步强度。研究在406种疾病和956个健康相关特征中识别出8149个ADP-疾病关联和36614个ADP-特征关联。步强度和昼夜节律成为与疾病关联最显著的ADP领域。此外,我们开发了一种名为可穿戴加速度计时间结构网络(WATSNet)的人工智能框架,在112种(28.1%)新发疾病和65种(34.0%)患病率疾病中实现了高区分度(AUC>0.7),例如帕金森病(AUC=0.873)和痴呆(AUC=0.841)。我们提供了与较低疾病风险相关的行为基准证据:每天至少0.8小时的中高强度身体活动、每日10000步以及每天7.8小时的睡眠。此外,我们在外部数据集(n=4406)中评估了ADP-疾病关联的泛化能力以及WATSNet的性能。这些发现共同提供了将数字行为与多种健康结果联系起来的全面景观(https://digital-phenome-atlas.com),并为精准健康监测奠定了基础。
基础研究 (12篇)
Protein aggregation is a hallmark of various neurodegenerative and systemic disorders, including Alzheimer's disease, Parkinson's disease, and type 2 diabetes. The ability to detect and characterize aggregates in both in vitro and in vivo systems is crucial for understanding disease mechanisms and developing diagnostic strategies. Fluorescent dyes have emerged as powerful tools for probing protein aggregates, offering insights into their structural variations and formation pathways. This review provides a comprehensive comparison of classical and emerging fluorescent dyes. It correlates their binding specificity and performance metrics, including quantum yield, fluorescence enhancement, and binding affinity, with molecular recognition mechanisms such as TICT restriction, π-π stacking, hydrophobic interactions, and electrostatic interactions. We categorize the dyes based on their blood-brain barrier (BBB) crossing ability, positron emission tomography (PET) imaging suitability, environmental sensitivity, nucleic acid binding affinity, luminescent conjugated oligothiophenes (LCOs), and nanoparticle-conjugation. We also consider their applicability to in vitro, in vivo and ex vivo settings, highlighting their use in detecting different aggregate species. We further assess dye suitability for amyloid versus amorphous aggregates and for different experimental contexts, considering critical parameters. By bridging structural features with functional outcomes, this review offers guidance for probe selection and highlights future directions for rational dye design to enhance sensitivity and selectivity in aggregate detection.
中文摘要:蛋白质聚集是包括阿尔茨海默病、帕金森病和2型糖尿病在内的多种神经退行性疾病及系统性疾病的重要特征。在体外和体内系统中检测和表征聚集体的能力对于理解疾病机制和开发诊断策略至关重要。荧光染料已成为探测蛋白质聚集体的有力工具,为揭示其结构变异和形成途径提供了见解。本综述对经典和新兴的荧光染料进行了全面比较,将其结合特异性及量子产率、荧光增强和结合亲和力等性能指标与TICT限制、π-π堆积、疏水相互作用和静电相互作用等分子识别机制相关联。我们根据染料的血脑屏障穿透能力、正电子发射断层扫描成像适用性、环境敏感性、核酸结合亲和力、发光共轭寡聚噻吩以及纳米颗粒偶联特性对染料进行了分类。同时考虑了它们在体外、体内和离体环境中的适用性,重点介绍了其在检测不同聚集物种中的应用。我们进一步评估了染料针对淀粉样蛋白与无定形聚集体的适用性以及针对不同实验背景的性能,并考量了关键参数。通过连接结构特征与功能结果,本综述为探针选择提供了指导,并强调了理性设计染料以提高聚集检测灵敏度和选择性的未来方向。
Glycosaminoglycans (GAGs) are polyanionic polysaccharides that colocalize with amyloid deposits in Alzheimer's disease, yet their mechanistic contribution to aggregation remains unclear. Here, we show that GAGs function as pH-responsive electrostatic scaffolds that selectively accelerate Aβ(1-42) aggregation under mildly acidic, early endosomal-like conditions but not at neutral pH. Combining experimental and computational approaches, we identify protonated N-terminal histidines as key determinants of GAG binding. Weak interactions between GAGs and the charged N-terminal region of Aβ promote conformational rearrangements that bring peptides into proximity and expose adjacent hydrophobic aggregation-prone segments, thereby facilitating peptide clustering. Kinetic analyses reveal that aggregation is enhanced in a way consistent with an apparent increase in effective peptide concentration, accelerating nucleation without altering the dominant aggregation pathway. Systematic variation of GAG chain length and sulfation level further demonstrates that aggregation enhancement requires a threshold degree of multivalency, consistent with a clustering-driven mechanism. Together, these findings establish a framework in which pH-dependent polyelectrolyte interactions act as molecular triggers of amyloid nucleation and define the physicochemical parameters that govern when GAGs transition from passive interaction partners to active promoters of Aβ aggregation, providing insight into how cellular microenvironments may regulate the earliest stages of Alzheimer's disease pathology.
中文摘要:糖胺聚糖(GAGs)是与阿尔茨海默病中淀粉样蛋白沉积共定位的多阴离子多糖,但其对聚集的机制性贡献尚不清楚。本研究显示,GAGs作为pH响应性静电支架,在轻度酸性、类似早期内体的条件下选择性加速Aβ(1-42)聚集,而在中性pH下则无此作用。结合实验与计算方法,我们确定质子化的N端组氨酸是GAG结合的关键决定因素。GAGs与Aβ带电N端区域之间的弱相互作用促进了构象重排,使肽段相互靠近并暴露相邻的疏水性聚集倾向片段,从而促进肽段聚类。动力学分析表明,聚集增强方式符合有效肽浓度表观增加的特征,加速了成核过程而不改变主要的聚集途径。系统改变GAG链长和硫酸化水平进一步证明,聚集增强需要达到多价性的阈值,这与聚类驱动机制一致。这些发现共同建立了一个框架,其中pH依赖性聚电解质相互作用作为淀粉样蛋白成核的分子触发器,并定义了决定GAGs何时从被动相互作用伙伴转变为Aβ聚集主动促进者的理化参数,为理解细胞微环境如何调节阿尔茨海默病病理的最早阶段提供了见解。
Soluble amyloid-β (Aβ) oligomers are widely implicated as neurotoxic species in Alzheimer's disease but remain difficult to characterize because their transient, heterogeneous assemblies are effectively invisible to conventional solution nuclear magnetic resonance (NMR) spectroscopy. Hydrostatic pressure (∼2.2 kbar) dissociates Aβ40 oligomers into monomers with sharp, intense resonances. Here, we exploit this pressure-dependent behavior to detect weak intermolecular contacts formed between small molecules and the NMR-invisible oligomers and read them out after pressure-induced dissociation. Using dimethyl sulfoxide (DMSO) as a simple small-molecule probe, we combine pressure-jump NMR with NOE difference spectroscopy to obtain residue-resolved DMSO-to-Aβ40-oligomer contacts. Because the resulting NOE signals are very weak, their detection requires substantial suppression of t1 noise that is shown to arise primarily from minute FID-to-FID phase and frequency instabilities. We therefore introduced RePAIR (Reference-based Phase And frequency Instability Reduction), a software package that uses an internal reference resonance to correct per-FID phase and frequency errors in gradient-encoded, phase-modulated data sets, suppressing t1 noise and revealing otherwise hidden intermolecular NOEs. The resulting contact profile shows preferential DMSO interactions with the ordered, hydrophobic β-sheet core of the Aβ40 oligomers. More broadly, this approach provides a framework for obtaining residue-resolved information on weak small-molecule interactions with transient protein assemblies that are otherwise inaccessible to conventional solution NMR.
中文摘要:可溶性淀粉样蛋白β(Aβ)寡聚体被广泛认为是阿尔茨海默病中的神经毒性物质,但由于其瞬态且异质的组装结构在常规溶液核磁共振(NMR)光谱中难以检测,因此其特征化一直存在困难。静水压力(约2.2 kbar)可将Aβ40寡聚体解离为单体,产生尖锐且强烈的共振信号。本研究利用这种压力依赖性行为,检测小分子与NMR不可见寡聚体之间形成的弱分子间接触,并在压力诱导解离后进行读取。以二甲基亚砜(DMSO)作为简单的小分子探针,我们结合压力跳跃NMR与NOE差谱技术,获得了残基水平的DMSO至Aβ40寡聚体接触信息。由于产生的NOE信号非常微弱,其检测需要大幅抑制t1噪声,该噪声主要源于微小的FID到FID相位和频率不稳定性。因此,我们引入了RePAIR(基于参考的相位和频率不稳定性减少)软件包,该软件利用内部参考共振来校正梯度编码、相位调制数据集中每个FID的相位和频率误差,从而抑制t1噪声并揭示原本隐藏的分子间NOE。所得接触谱显示DMSO优先与Aβ40寡聚体的有序疏水β折叠核心相互作用。更广泛地说,该方法为获取常规溶液NMR难以触及的瞬态蛋白质组装体上弱小分子相互作用的残基水平信息提供了一个框架。
Alzheimer's disease (AD) disrupts brain function in both spatial organization and temporal dynamics, which can be characterized by complementary fMRI and EEG measurements. In particular, fMRI provides higher spatial resolution to characterize multi-scale functional organization of brain networks, whereas EEG offers higher temporal resolution to capture dynamic neural activities across frequency bands. Thus, integrating the two modalities can characterize AD-related spatiotemporal disruptions more comprehensively than either modality alone. However, it is impractical to acquire paired fMRI and EEG data in real-world applications. To address this problem, we propose the fMRI-EEG Knowledge Transfer Network (FE-KTNet) to learn spatiotemporal representations from paired data and then transfer them back to modality-specific models through three stages. Specifically, in Stage 1, it learns modality-specific representations from fMRI and EEG FCNs, emphasizing multi-scale network organization for fMRI and frequency-specific electrophysiological coupling for EEG. Building on these representations, in Stage 2, it performs scale-wise bidirectional cross-modality fusion to integrate complementary information into fused multi-scale spatiotemporal representations. Finally, in Stage 3, it transfers the fused representations back to each modality-specific encoder through scale-wise feature alignment and logit-level knowledge distillation. We evaluate FE-KTNet on 14 multicenter datasets comprising 2,766 fMRI subjects and 1,842 EEG subjects, covering AD-NC, MCI-NC, and AD-MCI classifications. Compared with the corresponding baseline models, FE-KTNet increases fMRI-only and EEG-only accuracy by 3.4% and 6.1% for AD-NC classification, 5.2% and 8.0% for MCI-NC classification, and 3.5% and 7.1% for AD-MCI classification, respectively, and achieves the best overall performance among all evaluated methods. Our code is available at GitHub Repository.
中文摘要:阿尔茨海默病(AD)在空间组织和时间动态上破坏大脑功能,这可以通过互补的功能磁共振成像(fMRI)和脑电图(EEG)测量来表征。具体而言,fMRI提供更高的空间分辨率以表征脑网络的多尺度功能组织,而EEG提供更高的时间分辨率以捕获跨频带的动态神经活动。因此,整合这两种模态比单一模态更全面地表征与AD相关的时空紊乱。然而,在现实应用中获取配对的fMRI和EEG数据是不切实际的。为解决此问题,我们提出了fMRI-EEG知识转移网络(FE-KTNet),从配对数据中学习时空表示,然后通过三个阶段将其转移回特定模态的模型。具体而言,在第一阶段,它从fMRI和EEG的功能连接网络(FCNs)中学习特定模态的表示,强调fMRI的多尺度网络组织和EEG的频率特异性电生理耦合。基于这些表示,在第二阶段,它执行按尺度的双向跨模态融合,将互补信息整合到融合的multi-scale时空表示中。最后,在第三阶段,它通过按尺度的特征对齐和logit级别的知识蒸馏将融合后的表示转移回每个特定模态的编码器。我们在14个多中心数据集上评估了FE-KTNet,包含2766名fMRI受试者和1842名EEG受试者,涵盖AD-NC、MCI-NC和AD-MCI分类。与相应的基线模型相比,FE-KTNet在AD-NC分类中使仅fMRI和仅EEG的准确率分别提高3.4%和6.1%,在MCI-NC分类中提高5.2%和8.0%,在AD-MCI分类中提高3.5%和7.1%,并在所有评估方法中实现了最佳的整体性能。我们的代码可在GitHub仓库获取。
Circadian disruptions perturb the brain and immune system and increase the risk of developing Alzheimer's disease (AD), yet whether this involves dysregulation of brain immunity remains less clear. Here, we performed single-cell RNA sequencing of the brain immune compartment around the day-night cycle and identified brain border-associated macrophages (BAMs) as highly rhythmic cells. We found that the rest phase was a specialized time for BAM engulfment, characterized by upregulation of endocytic machinery and enhanced uptake of fluid-borne material including amyloid-beta (Aβ). Rhythmicity in BAM scavenging was regulated by the clock gene Bmal1, mediated by the scavenger receptor CD206, and perturbed with age. In a mouse model of AD, deletion of Bmal1 in BAMs worsened perivascular and leptomeningeal Aβ plaque burden. Our results characterize rapid endocytosis as a specialized and rhythmic BAM function and identify perturbed timing of brain border immunity as one avenue by which circadian disruptions may precipitate amyloidosis.
中文摘要:昼夜节律紊乱会干扰大脑和免疫系统并增加患阿尔茨海默病(AD)的风险,但这一过程是否涉及大脑免疫失调尚不明确。本研究在昼夜周期内对大脑免疫区室进行了单细胞RNA测序,发现脑边界相关巨噬细胞(BAMs)是高度具有节律性的细胞。我们发现静息期是BAM吞噬作用的特殊时段,其特征为内吞机制上调以及包括淀粉样蛋白β(Aβ)在内的流体携带物质摄取增强。BAM清除作用的节律性由时钟基因Bmal1调控,通过清道夫受体CD206介导,并随年龄增长而紊乱。在AD小鼠模型中,敲除BAMs中的Bmal1会加重血管周围和软脑膜的Aβ斑块负荷。我们的结果将快速内吞作用表征为一种特殊的节律性BAM功能,并指出大脑边界免疫时间的紊乱是昼夜节律紊乱诱发淀粉样变性的途径之一。
Biomedical research is constrained by the time and domain expertise required to analyze increasingly large and complex datasets. Here we present OpenScientist, an open-source agentic AI co-scientist designed to address this gap by investigating scientist-defined queries and generating verifiable, data-grounded analyses. OpenScientist was evaluated by domain experts across five biomedical case studies, completing analyses in minutes that otherwise would take months of human time and expertise. It accurately quantified Alzheimer's blood biomarker performance, generated a plasma proteomic survival model that predicted survival in a hidden-evaluation cohort, proposed a reproducible mechanism linking tau pathology to altered lysosomal acidification, generated multiple myeloma hypotheses validated in an external cohort with attenuated signal in randomized controls, and demonstrated concordance with an independent human analysis in a blinded, prespecified proteomic comparison. These results support the use of OpenScientist to assist biomedical data analysis in concert with human experts. To support research involving sensitive clinical datasets, OpenScientist can operate in a fully air-gapped environment using open-source models for inference. OpenScientist demonstrates that open, auditable, agentic AI can support real-world clinical research by researching the literature, generating hypotheses, executing analyses, and generating insights from complex datasets.
中文摘要:生物医学研究受限于分析日益庞大和复杂数据集所需的时间与领域专业知识。本文提出OpenScientist,这是一种开源的智能体AI联合科学家,旨在通过调查科学家定义的查询并生成可验证、基于数据的分析来弥补这一空白。OpenScientist在五个生物医学案例研究中接受了领域专家的评估,其完成的分析原本需要数月的人类时间和专业知识,而它仅需几分钟即可完成。它准确量化了阿尔茨海默病血液生物标志物的性能,生成了一个血浆蛋白质组学生存模型,该模型能在隐藏评估队列中预测生存率;提出了连接tau病理与溶酶体酸化改变的机制假设;生成了在外部队列中得到验证的多发性骨髓瘤假说,尽管随机对照试验中的信号减弱;并在盲法预设的蛋白质组比较中展示了与独立人类分析的一致性。这些结果支持将OpenScientist用于协助生物医学数据分析,并与人类专家协同工作。为了支持涉及敏感临床数据集的研究,OpenScientist可以使用开源模型进行推理,在完全物理隔离的环境中运行。OpenScientist证明了开放、可审计的智能体AI可以通过研究文献、生成假设、执行分析并从复杂数据集中生成见解,从而支持现实世界的临床研究。
Excess lipid accumulation and a sedentary lifestyle are associated with metabolic dysfunction-associated fatty liver disease (MAFLD), but the causal mechanisms and preventive methods are not fully understood. Macroautophagy/autophagy is a lysosomal degradation pathway robustly induced by exercise and plays a key role in lipid metabolism. Understanding the mechanisms by which exercise activates autophagy and elicits metabolic benefits in the liver will provide important insights into the pathogenesis of MAFLD. Here, we discovered negative correlations between expression and lactylation of WDR41 (WD repeat domain 41) and pathogenesis of a series of human hepatic metabolic diseases. We found that WDR41 was a pro-autophagy protein that underwent lactylation in response to autophagy-inducing conditions, such as exercise. WDR41 was lactylated at lysine 319 (K319), a modification facilitated by LDHA (lactate dehydrogenase A) upon autophagy induction, and delactylated by SIRT2 (sirtuin 2). Lactylated WDR41 promoted autophagy initiation by directly interacting with the autophagy proteins ATG13 (autophagy related 13) and RB1CC1/FIP200 (RB1 inducible coiled-coil 1) and driving the ULK1 (unc-51 like autophagy activating kinase 1) complex assembly. Physiologically, WDR41 and WDR41K319 lactylation, were important for exercise-induced improvements in insulin sensitivity and lipid metabolism against excess lipid accumulation in the liver. Thus, we demonstrated that WDR41 lactylation at K319 is an important regulatory mechanism by which exercise regulates autophagy and hepatic glucose and lipid metabolism.Abbreviations: AV: adeno-associated virus; ALS: amyotrophic lateral sclerosis; ALT: alanine aminotransferase; AMPK: AMP-activated protein kinase; ANOVA: analysis of variance; AST: aspartate aminotransferase; ATG13: autophagy related 13; BECN1: beclin 1; C9orf72: C9orf72-SMCR8 complex subunit; cDNA: complementary DNA; co-IP: co-immunoprecipitation; CQ: chloroquine; CRISPR: clustered regularly interspaced short palindromic repeats; EBSS: Earle's balanced salt solution; EE: energy expenditure; FN1/fibronectin: fibronectin 1; FTD: frontotemporal dementia; GAP: GTPase-activating protein; GEF: guanine nucleotide exchange factor; GFP: green fluorescent protein; gRNA: guide RNA; GST: glutathione S-transferase; GTT: glucose tolerance test; H&E: hematoxylin and eosin; HDAC: histone deacetylase; HFD: high-fat diet; i.p.: intraperitoneal; IP: immunoprecipitation; ITT: insulin tolerance test; KO: knockout; LC-MS/MS: liquid chromatography-tandem mass spectrometry; LDHA: lactate dehydrogenase A; MAFLD: metabolic dysfunction-associated fatty liver disease; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MASH: metabolic dysfunction-associated steatohepatitis; mRFP: monomeric red fluorescent protein; MS: mass spectrometry; MS/MS: tandem mass spectrometry; MTOR: mechanistic target of rapamycin kinase; NAS: NAFLD activity score; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PTT: pyruvate tolerance test; PVDF: polyvinylidene fluoride; RB1CC1/FIP200: RB1 inducible coiled-coil 1; RD: regular diet; RER: respiratory exchange ratio; SDS: sodium dodecyl sulfate; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM: standard error of the mean; siRNA: small interfering RNA; SIRT2: sirtuin 2; SMCR8: SMCR8-C9orf72 complex subunit; SQSTM1/p62: sequestosome 1; STING1: stimulator of interferon response cGAMP interactor 1; TBG: thyroxine-binding globulin; TC: total cholesterol; TG: triglyceride; ULK1: unc-51 like autophagy activating kinase 1; ULK2: unc-51 like autophagy activating kinase2; UN: untreated; VCO2: carbon dioxide production; VO2: oxygen consumption; WB: western blotting; WDR41: WD repeat domain 41; WT: wild type.
中文摘要:脂质过度积累和久坐生活方式与代谢功能障碍相关脂肪性肝病(MAFLD)有关,但其因果机制和预防方法尚未完全阐明。大自噬/自噬是一种溶酶体降解途径,由运动强烈诱导并在脂质代谢中发挥关键作用。了解运动激活自噬并产生肝脏代谢益处的机制将为理解MAFLD的发病机制提供重要见解。在此,我们发现WDR41(WD重复结构域蛋白41)的表达和乳酸化与一系列人类肝脏代谢疾病的发病呈负相关。我们发现WDR41是一种促自噬蛋白,在运动等自噬诱导条件下会发生乳酸化。WDR41在第319位赖氨酸(K319)发生乳酸化,该修饰由LDHA(乳酸脱氢酶A)在自噬诱导时促进,并由SIRT2去乳酸化。乳酸化的WDR41通过直接与自噬蛋白ATG13和RB1CC1/FIP200相互作用并驱动ULK1复合物组装来促进自噬起始。在生理状态下,WDR41及其K319位点的乳酸化对于运动改善胰岛素敏感性和脂质代谢以对抗肝脏过度脂质积累至关重要。因此,我们证明了WDR41在K319位的乳酸化是运动调节自噬以及肝脏葡萄糖和脂质代谢的重要调控机制。
In this work, a PtPd/CeO2 heterostructure nanozyme-synergistically modulated ternary ZnS/CdS/Bi2Se3 electrochemiluminescence/photoelectrochemical (ECL/PEC) aptasensor was designed for simultaneous detection of amyloid-β peptides (Aβ1-40 and Aβ1-42), as the key plasma biomarkers of Alzheimer's disease (AD). Benefiting from the bimetallic alloy effect and the support-active component synergy, PtPd/CeO2 heterostructure efficiently accelerated interfacial electron transfer, leading to both an improved catalytic reaction kinetic rate and enhanced adsorption and activation of reactants. Ternary ZnS/CdS/Bi2Se3 achieved photocurrent self-enhancement via synergistic bandgap excitation and multi-interface charge transfer effects among its components, thereby significantly boosting the response signals of both ECL and PEC. Through the integration of aptamer-mediated specific target recognition and toehold-triggered strand displacement reaction (TSDR)-based signal amplification, this aptasensor realized the simultaneous detection of Aβ1-42 and Aβ1-40. Notably, practical validation of the aptasensor for Aβ1-42/Aβ1-40 ratio detection in actual plasma specimens demonstrated the feasibility of minimally invasive liquid biopsy with high patient compliance and great potential for large-scale screening and early diagnosis of AD.
中文摘要:本研究设计了一种由PtPd/CeO2异结构纳米酶协同调控的三元ZnS/CdS/Bi2Se3电化学发光/光电化学(ECL/PEC)适配体传感器,用于同时检测阿尔茨海默病(AD)的关键血浆生物标志物淀粉样蛋白β肽(Aβ1-40和Aβ1-42)。得益于双金属合金效应与支持活性组分的协同作用,PtPd/CeO2异结构有效加速了界面电子转移,从而提高了催化反应动力学速率并增强了反应物的吸附与活化。三元ZnS/CdS/Bi2Se3通过组分间的协同带隙激发和多界面电荷转移效应实现光电流自增强,显著提升了ECL和PEC的响应信号。该适配体传感器通过整合适配体介导的特异性靶标识别和基于触发动作链置换反应(TSDR)的信号放大,实现了Aβ1-42和Aβ1-40的同时检测。在实际血浆样本中验证了该适配体传感器对Aβ1-42/Aβ1-40比值的检测能力,证明了微创液体活检的可行性,其具有高患者依从性,在AD的大规模筛查和早期诊断方面具有巨大潜力。
Alzheimer's disease (AD) is a common neurodegenerative disorder. Compared to the limited specificity of single-biomarker detection, the combined detection of multiple biomarkers can significantly improve the accuracy of AD diagnosis. In this study, a field-effect transistor (FET) biosensor array integrating four independently functionalized regions was fabricated by modifying carbon nanotube (CNT) surfaces with amyloid bovine serum albumin (AL-BSA) nanofilm as an antifouling layer, enabling the simultaneous detection of multiple tau proteins. The proposed FET biosensor exhibited excellent anti-fouling performance while maintaining high sensitivity, with detection limits as low as 3.3 fg/mL, 0.17 fg/mL, 0.02 fg/mL, and 2.5 fg/mL for p-tau181, p-tau217, p-tau231, and t-tau, respectively. Evaluation of 35 clinical serum samples indicated that p-tau181 outperformed the other three tau proteins as an AD diagnostic biomarker. By further incorporating a support vector machine (SVM)-based machine learning algorithm and employing multi-biomarker co-detection, the accuracy of AD diagnosis can be improved to nearly 100%. This study provides a novel strategy for array FET biosensors with high clinical application potential for the precise detection of AD.
中文摘要:阿尔茨海默病(AD)是一种常见的神经退行性疾病。与单一生物标志物检测有限的特异性相比,多种生物标志物的联合检测可显著提高AD诊断的准确性。本研究通过用淀粉样牛血清白蛋白(AL-BSA)纳米薄膜修饰碳纳米管(CNT)表面作为抗污层,制造了一种集成四个独立功能化区域的场效应晶体管(FET)生物传感器阵列,实现了多种tau蛋白的同时检测。所提出的FET生物传感器在保持高灵敏度的同时表现出优异的抗污性能,对p-tau181、p-tau217、p-tau231和t-tau的检测限分别低至3.3 fg/mL、0.17 fg/mL、0.02 fg/mL和2.5 fg/mL。对35个临床血清样本的评估表明,与其他三种tau蛋白相比,p-tau181作为AD诊断生物标志物表现更优。通过进一步结合基于支持向量机(SVM)的机器学习算法并采用多生物标志物共检测,AD诊断准确率可提高至近100%。本研究为具有较高临床应用潜力的阵列FET生物传感器提供了一种新策略,用于AD的精准检测。
Early diagnosis for Alzheimer's disease (AD) is vital for effective therapeutic intervention and improved patient prognosis. In this work, we developed a highly sensitive electrochemiluminescence (ECL) aptasensor for detecting a key AD biomarker, Tau protein. An all-inorganic perovskite CsPbBr3 nanocrystals (NCs) were used as ECL emitters and were encapsulated with polyvinylpyrrolidone (PVP) to improve the stability of CsPbBr3 NCs in aqueous solution. Moreover, -PVP encapsulation significantly enhanced the ECL response via coordination between the lone-pair electrons of oxygen atoms and Pb2+. The obtained CsPbBr3@PVP composite was further functionalized with gold nanoparticles, which served as anchoring sites for the immobilization of a Tau-specific aptamer. The sensing mechanism relies on the specific recognition between the surface-bound aptamer and the Tau protein. The formation of the aptamer-target complex impeded the ECL reaction efficiency of the system, resulting in an "off" ECL sensing response. This strategy enables ultrasensitive detection of Tau protein with a wide linear range from 10 fg/mL to 108 fg/mL and a detection limit as low as 0.80 fg/mL. The aptasensor also demonstrated satisfactory recoveries of 97.2% to 108.6% in mouse cerebrospinal fluid with relative standard deviations below 6.5%, indicating its promising potential for early diagnosis of AD.
中文摘要:阿尔茨海默病早期诊断对有效治疗干预和改善患者预后至关重要。本研究开发了一种高灵敏度电化学发光适配体传感器用于检测关键阿尔茨海默病生物标志物Tau蛋白。采用全无机钙钛矿CsPbBr3纳米晶体作为电化学发光发射体,并用聚乙烯吡咯烷酮包裹以提高其在aqueous溶液中的稳定性。此外,通过氧原子孤对电子与Pb2+的配位作用,该包裹显著增强了电化学发光响应。将所得CsPbBr3@PVP复合物进一步用金纳米颗粒功能化,作为固定Tau特异性适配体的锚定位点。传感机制依赖于表面固定适配体与Tau蛋白之间的特异性识别。适配体-靶标复合物的形成阻碍了系统的电化学发光反应效率,从而产生关断型电化学发光传感响应。该策略实现了Tau蛋白的超灵敏检测,线性范围宽达10 fg/mL至108 fg/mL,检测限低至0.80 fg/mL。该适配体传感器在小鼠脑脊液中也表现出97.2%至108.6%的可满意回收率,相对标准偏差低于6.5%,显示出其在阿尔茨海默病早期诊断中的广阔潜力。
Mitophagy, the selective clearance of defective mitochondria via the autophagy-lysosome pathway, is essential for maintaining mitochondrial health and cellular homeostasis. Dysregulation of mitophagy is strongly implicated in aging-related pathologies, including neurodegenerative diseases (Alzheimer's, Parkinson's), cancer, and metabolic disorders, highlighting the significance of elucidating its regulatory mechanisms. While existing methods using exogenous reporters enable genome-wide and high-throughput screening for mitophagy regulators, they constrain discoveries to specific pathways and introduce artifacts through ectopic expression. To overcome these limitations, we developed an effective and rapid platform for identifying mitophagy modulators by targeting endogenous proteins. Using CRISPR-Cas9 technology, we engineered HeLa cells expressing small molecular tags (GFP or NanoLuc) fused to the C-terminal of ATP5B, a mitochondrial inner membrane protein. Genome-wide screening for mitophagy regulatory genes were performed using a genome-wide CRISPR library coupled with flow cytometry. Additionally, an FDA-approved kinase inhibitor library was used to screen for mitophagy inducers. To evaluate the efficacy of a screened drug in Alzheimer's disease, cognitive behavior, pathological features and mitophagy events in 3 × Tg-AD mice with or without treatment were examined using the Morris water maze assay, enzyme-linked immunosorbent assay (ELISA) and transmission electron microscopy (TEM). These ATP5B-tagging cells provided a robust readout of mitophagy and enabled high-throughput genetic or pharmacological screening. With this platform, we identified several promising genes that regulate mitophagy and are significantly associated with Alzheimer's disease. Moreover, the FDA-approved drug Flupentixol emerged as a novel mitophagy inducer that acts by promoting adenosine monophosphate-activated protein kinase (AMPK) localization to mitochondria and exhibited strong therapeutic potential in a model of Alzheimer's disease. This study establishes a novel system for identifying mitophagy modulators, with the potential to accelerate the discovery of therapeutic strategies for Alzheimer's disease.
中文摘要:线粒体自噬是通过自噬溶酶体途径选择性清除缺陷线粒体的过程,对维持线粒体健康和细胞稳态至关重要。线粒体自噬失调与衰老相关病理改变密切相关,包括神经退行性疾病(阿尔茨海默病、帕金森病)、癌症和代谢紊乱,这突显了阐明其调控机制的重要性。虽然现有的使用外源报告基因的方法能够实现全基因组和高通量筛选线粒体自噬调节因子,但它们将发现限制在特定通路中,并通过异位表达引入人工假象。为了克服这些局限性,我们开发了一种针对内源性蛋白的有效且快速的平台来识别线粒体自噬调节剂。利用CRISPR-Cas9技术,我们构建了HeLa细胞,其ATP5B(一种线粒体内膜蛋白)C端融合了小分子标签(GFP或NanoLuc)。使用全基因组CRISPR文库结合流式细胞术进行了线粒体自噬调节基因的全基因组筛选。此外,还使用了FDA批准的激酶抑制剂库来筛选线粒体自噬诱导剂。为了评估筛选出的药物在阿尔茨海默病中的疗效,我们利用莫里斯水迷宫实验、酶联免疫吸附测定(ELISA)和透射电子显微镜(TEM)检查了接受或不接受治疗的3×Tg-AD小鼠的认知行为、病理特征和线粒体自噬事件。这些ATP5B标记细胞提供了强大的线粒体自噬读数,并实现了高通量遗传或药理学筛选。利用该平台,我们鉴定了几个调节线粒体自噬并与阿尔茨海默病显著相关的有前景的基因。此外,FDA批准的药物氟哌噻吨被发现是一种新的线粒体自噬诱导剂,它通过促进腺苷单磷酸激活蛋白激酶(AMPK)定位到线粒体发挥作用,并在阿尔茨海默病模型中表现出强大的治疗潜力。本研究建立了一种识别线粒体自噬调节因子的新系统,有望加速阿尔茨海默病治疗策略的发现。
Alzheimer's disease (AD) exhibits region- and cell-type-specific vulnerability, yet the underlying regulatory mechanisms remain poorly defined. We performed integrated single-nucleus RNA-seq and ATAC-seq of human hippocampus to resolve gene regulatory architecture in AD. By linking chromatin accessibility to transcription, we identified more than 1000 disease-associated cis-regulatory interactions, highlighting coordinated epigenomic-transcriptomic remodeling. Excitatory cornu ammonis (EX.CA) neurons exhibited disproportionate regulatory disruption, characterized by increased chromatin accessibility coupled to activation of apoptosis-related gene programs, whereas dentate gyrus (EX.DG) neurons remained comparatively resistant. In glial cells, regulatory network inference revealed activation of transcription factor modules centered on SPI1/KLF4 in microglia and STAT3 in astrocytes, defining epigenetic programs that are highly associated with inflammatory and metabolic state transitions. Comparative evaluation with the prefrontal cortex uncovered conserved inflammatory activation alongside region-specific immune regulatory divergence, indicating spatially distinct microglial responses. Furthermore, cross-species integration demonstrated that a substantial fraction of AD-associated regulatory elements are human-specific, with AD-risk variants enriched in microglial cis-regulatory elements at loci including BIN1 and APOE. Together, these results provide a mechanistic framework linking chromatin remodeling to cell-type-specific dysfunction and reveal human-specific regulatory architecture as a crucial factor to AD vulnerability and translational limitation.
中文摘要:阿尔茨海默病表现出区域和细胞类型特异性的易感性,但其潜在的调控机制尚不明确。我们对人类海马体进行了整合的单核RNA测序和ATAC测序,以解析阿尔茨海默病中的基因调控架构。通过关联染色质可及性与转录,我们鉴定出超过1000个疾病相关的顺式调控相互作用,突出了协调的表观基因组-转录组重塑。兴奋性CA区神经元表现出不成比例的调控破坏,其特征是染色质可及性增加并伴随凋亡相关基因程序的激活,而齿状回神经元则相对具有抵抗力。在胶质细胞中,调控网络推断揭示了小胶质细胞中以SPI1/KLF4为中心的转录因子模块激活以及星形胶质细胞中STAT3的激活,定义了与炎症和代谢状态转换高度相关的表观遗传程序。与前额叶皮层的比较评估揭示了保守的炎症激活以及区域特异性免疫调控差异,表明空间特异性的小胶质细胞反应。此外,跨物种整合表明,相当比例的阿尔茨海默病相关调控元件是人类特有的,阿尔茨海默病风险变异富集在包括BIN1和APOE在内的位点的小胶质细胞顺式调控元件中。综上所述,这些结果提供了一个将染色质重塑与细胞类型特异性功能障碍联系起来的机制框架,并揭示了人类特异性调控架构作为阿尔茨海默病易感性和转化局限性的关键因素。
2脑血管病与卒中 (19篇)
临床研究 (13篇)
The extent to which blood pressure (BP) and arterial stiffness mediate the association between long-term PM2.5 exposure and cardiovascular risk, and whether individuals with metabolic impairment are more susceptible, remain unclear. Within the "Risk of Cardiovascular diseases and abdominal aortic Aneurysms in Varese" (RoCAV) cohort, we retained 2119 men aged 50-75 and free of coronary heart disease (CHD) and stroke at baseline; carotid-femoral Pulse Wave Velocity (cfPWV) was measured in a subset of 1015 using an automated oscillometer. Exposure was the 12-month mean PM2.5 concentration before baseline (EXPANSE models); outcome was incident major acute CHD or stroke (MACE), fatal or non-fatal. We estimated the mediating contribution of BP and cfPWV through Marginal Structural Models and Aalen survival models, with individual- and area-level confounders. In a median follow-up of 7.6 years, 178 MACE events occurred (rate=1155 per 100,000 person-years), and 76 (1086/100,000 p-y) in the cfPWV subset. Systolic BP, mean BP, brachial pulse pressure and cfPWV were highest in the most exposed. Each 1-µg/m3 increase in PM2.5 was associated with 151 (95%CI:21-282) additional MACE events per 100,000 p-y, of which 48 (95%CI:17-79) were mediated by cfPWV (mediated proportion: 32%). Systolic BP and brachial pulse pressure each mediated about 16% of the PM2.5-associated risk. The cfPWV-mediated effect was enhanced in men with impaired glucose (96;95%CI:38-155) and elevated LDL-cholesterol (88;95%CI:28-147). Large-artery stiffness substantially contributes to the MACE burden associated with chronic PM2.5 exposure, especially in men with metabolic impairment. Monitoring cfPWV may help incorporate environmental risk into cardiovascular prevention.
中文摘要:长期PM2.5暴露与心血管风险之间关联的血压及动脉僵硬度中介作用程度,以及代谢受损个体是否更易感仍不明确。在RoCAV队列中,我们纳入了基线时无冠心病和卒中病史的2119名50至75岁男性;其中1015人亚组使用自动示波法测量颈股脉搏波传导速度(cfPWV)。暴露指标为基线前12个月的平均PM2.5浓度,结局为首次发生主要急性冠心病或卒中事件。我们利用边际结构模型和Aalen生存模型,在控制个体及区域水平混杂因素后,估算血压和cfPWV的中介贡献率。中位随访7.6年间共发生178例MACE事件(发生率1155/10万人年),cfPWV亚组发生76例(1086/10万人年)。最高暴露组的收缩压、平均压、肱动脉脉压及cfPWV均最高。PM2.5每增加1µg/m3,MACE事件额外增加151例(95%CI:21-282),其中48例(95%CI:17-79)由cfPWV中介(中介比例32%)。收缩压和肱动脉脉压各中介约16%的PM2.5相关风险。在葡萄糖受损和低密度脂蛋白胆固醇升高男性中,cfPWV介导效应增强。大动脉僵硬度对慢性PM2.5暴露相关的MACE负担贡献显著,尤其在代谢受损男性中。监测cfPWV有助于将环境风险纳入心血管预防。
Depression, anxiety, and fatigue are common and disabling long-term sequelae of stroke. Whether habitual physical activity before stroke and engagement in physical activity during recovery are associated with poststroke psychological outcomes remains incompletely understood. We investigated associations between physical activity patterns and psychological outcomes during the first year after ischemic stroke. In this prospective cohort study, consecutive patients with ischemic stroke enrolled in the STROKE-CARD Registry were assessed for depression, anxiety, and fatigue at either 3- or 12-month follow-up after stroke using the Hospital Anxiety and Depression Scale and Fatigue Severity Scale. Physical activity was assessed before and after stroke with the Baecke Questionnaire. Associations between physical activity and psychological outcomes were assessed using multivariable logistic regression adjusted for age, sex, body mass index, prestroke and poststroke disability, stroke severity and localization, thrombolysis, prestroke depression, and cognitive impairment. Within 1050 patients (median age, 70 years; 35% female), 35.3% were screened positive for depression, 29.9% for anxiety, and 53.2% for fatigue at either 3 or 12 months after stroke. Both prestroke and poststroke physical activity were associated with lower odds of depression (adjusted odds ratio, 0.47 [95% CI, 0.36-0.62] and 0.45 [95% CI, 0.34-0.59]; P<0.001) and fatigue (adjusted odds ratio, 0.49 [95% CI, 0.38-0.64] and 0.49 [95% CI, 0.38-0.64]; P<0.001), and with lower odds of anxiety (adjusted odds ratio, 0.75 [95% CI, 0.57-1.00]; P=0.050) and (adjusted odds ratio, 0.71 [95% CI, 0.53-0.94]; P=0.016). High-intensity and high-volume activities were associated with the lowest prevalence of depression and fatigue (depression, 24.5%-25.7%; fatigue, 40.8%-44.1%). Endurance sports were associated with lower rates of depression (22.2%; P<0.001) and fatigue (40.6%; P<0.001), whereas strength training was associated with lower anxiety (12.8%; P=0.003). Physical activity before and after stroke was associated with lower odds of depression, anxiety, and fatigue. These findings identify physical activity as a potentially modifiable behavioral factor associated with psychological well-being after stroke and support further evaluation in intervention studies.
中文摘要:抑郁、焦虑和疲劳是卒中常见且致残的长期后遗症。卒中前习惯性体力活动及恢复期参与体力活动与卒中后心理结局的关联尚不完全明确。本研究调查了缺血性卒中后第一年内体力活动模式与心理结局的关联。在这项前瞻性队列研究中,纳入STROKE-CARD注册库的连续缺血性卒中患者,在卒中后3个月或12个月随访时采用医院焦虑抑郁量表和疲劳严重程度量表评估抑郁、焦虑和疲劳。使用Baecke问卷评估卒中前和卒中后的体力活动。采用多变量逻辑回归分析体力活动与心理结局的关联,调整因素包括年龄、性别、体重指数、卒中前后残疾程度、卒中严重程度和定位、溶栓治疗、卒中前抑郁及认知障碍。在1050名患者(中位年龄70岁,女性占35%)中,卒中后3个月或12个月筛查出抑郁阳性率为35.3%,焦虑为29.9%,疲劳为53.2%。卒中前和卒中后的体力活动均与较低的抑郁(调整比值比分别为0.47 [95% CI, 0.36-0.62]和0.45 [95% CI, 0.34-0.59];P<0.001)和疲劳(调整比值比均为0.49 [95% CI, 0.38-0.64]和0.49 [95% CI, 0.38-0.64];P<0.001)几率相关,并与较低的焦虑几率相关(调整比值比分别为0.75 [95% CI, 0.57-1.00];P=0.050和0.71 [95% CI, 0.53-0.94];P=0.016)。高强度和高容量活动与最低的抑郁和疲劳患病率相关(抑郁24.5%-25.7%;疲劳40.8%-44.1%)。耐力运动与较低的抑郁发生率(22.2%;P<0.001)和疲劳发生率(40.6%;P<0.001)相关,而力量训练与较低的焦虑发生率(12.8%;P=0.003)相关。卒中前和卒中后的体力活动均与较低的抑郁、焦虑和疲劳几率相关。这些发现表明体力活动是与卒中后心理福祉相关的潜在可改变行为因素,支持在干预研究中进一步评估。
Daily physiological homoeostasis varies with time of day, following diurnal cycles partially regulated by the central autonomic network (CAN). Experimental studies suggest that acute ischaemic stroke disrupts these rhythms, impairing recovery, but translation to humans has been limited by the lack of robust methods to quantify diurnal phase shifts. We developed a framework that uses continuous heart rate data to characterise shifts in diurnal cardiac rhythms relative to the phase expected at a given time of day, providing a dynamic marker of heart-brain axis function. We applied this approach to retrospective data from patients with ischaemic stroke in the Charité-Universitätsmedizin Berlin Data Warehouse (DWC) and the MIMIC-III/IV cohorts, quantifying rhythm shifts and examining their associations with lesion size, location, and clinical outcomes. Stroke was associated with systematic disruption of diurnal cardiac cycles, with larger shifts associated with worse clinical scores, impaired short-term recovery, and higher mortality. Within the CAN, greater rhythm shifts corresponded to larger infarcts, indicating region-specific vulnerability. These findings identify diurnal cardiac rhythm shifts as a clinically accessible biomarker of heart-brain-axis function. Given the observational design, these associations are hypothesis-generating and require prospective validation. The Schilling Foundation and the Schilling Professorship, DFG EXC-2049/NeuroCure.
中文摘要:日常生理稳态随时间变化,遵循由中枢自主网络部分调节的昼夜节律。实验研究表明急性缺血性卒中会破坏这些节律并损害恢复,但由于缺乏量化昼夜相位偏移的可靠方法,向人类临床转化的研究有限。我们开发了一种利用连续心率数据来表征相对于给定时间预期相位的昼夜心脏节律偏移的框架,从而提供反映心脑轴功能的动态标志物。我们将该方法应用于柏林夏里特医科大学数据仓库及MIMIC-III/IV队列中缺血性卒中患者的回顾性数据,量化了节律偏移并考察其与病灶大小、位置及临床结局的关联。卒中与昼夜心脏节律的系统性破坏相关,较大的偏移与较差的临床评分、短期恢复受损及更高死亡率相关。在中枢自主网络内,更大的节律偏移对应于更大的梗死面积,提示区域特异性易感性。这些发现将昼夜心脏节律偏移确定为一种临床可及的心脑轴功能生物标志物。鉴于观察性研究设计,这些关联仅为生成假设,需前瞻性验证。本研究由Schilling基金会和Schilling教授职位、DFG EXC-2049/NeuroCure资助。
Bariatric surgery and pharmacological weight-loss therapies improve cardiometabolic risk factors. However, direct head-to-head comparisons assessing their impact on cardiovascular outcomes remain limited. We performed an exploratory meta-analysis to compare bariatric surgery and pharmacological weight-loss therapies on major clinical outcomes in adults with obesity. A systematic literature search using PubMed and Scopus databases was conducted. Randomized and observational studies comparing bariatric surgery or incretin receptor agonists with controls were included in the analysis. The primary outcomes were all-cause mortality and MACE. A frequentist random-effects network meta-analysis was conducted across three nodes. A total of 40 studies, comprising more than 1.9 million patients, were included in the meta-analysis. Compared with control, bariatric surgery was associated with a significant reduction in all evaluated outcomes, including all-cause mortality (HR:0.57, 95%CI:0.51-0.65), MACE (HR:0.54, 95%CI:0.45-0.64), cardiovascular mortality, heart failure hospitalization, myocardial infarction, and stroke. Incretin receptor agonists were also associated with lower all-cause mortality (HR:0.62, 95%CI:0.52-0.74), lower MACE (HR:0.75, 95%CI:0.61-0.92) and reduced heart failure hospitalization. All-cause mortality-representing the most direct and clinically relevant endpoint-did not differ significantly between the two strategies in the exploratory network meta-analysis. Importantly, the network estimates should be cautiously interpreted, given the predominance of observational evidence, substantial heterogeneity, and very low confidence across all comparisons. Bariatric surgery and incretin receptor agonists are associated with substantial reductions in major cardiovascular outcomes in adults with obesity. In head-to-head comparisons, no significant differences were observed in all-cause mortality and stroke. Both strategies provide clinically meaningful benefits.
中文摘要:减重手术和药理学减重疗法可改善心血管代谢危险因素。然而,直接比较其对心血管结局影响的头对头研究仍然有限。我们进行了一项探索性荟萃分析,以比较减重手术和药理学减重疗法对肥胖成年人的主要临床结局的影响。通过 PubMed 和 Scopus 数据库进行了系统文献检索。纳入随机研究和观察性研究,比较减重手术或肠促胰岛素受体激动剂与对照组的差异。主要结局指标为全因死亡率和主要不良心血管事件(MACE)。采用频率学派随机效应网络荟萃分析在三个节点上进行。共纳入40项研究,涉及超过190万患者。与对照组相比,减重手术与所有评估结局的显著降低相关,包括全因死亡率(HR:0.57,95%CI:0.51-0.65)、MACE(HR:0.54,95%CI:0.45-0.64)、心血管死亡率、心力衰竭住院、心肌梗死和中风。肠促胰岛素受体激动剂也与较低的全因死亡率(HR:0.62,95%CI:0.52-0.74)、较低的MACE(HR:0.75,95%CI:0.61-0.92)以及减少的心力衰竭住院相关。在探索性网络荟萃分析中,代表最直接且临床相关终点的全因死亡率在这两种策略之间无显著差异。重要的是,鉴于观察性证据占主导地位、异质性较大以及所有比较的置信度极低,应对网络估计结果谨慎解读。减重手术和肠促胰岛素受体激动剂与肥胖成年人主要心血管结局的大幅降低相关。在头对头比较中,全因死亡率和中风未观察到显著差异。两种策略均提供具有临床意义的益处。
The association of long working hours with cardiometabolic disease accumulation remains unclear. Cardiometabolic multimorbidity (CMM) was defined as the coexistence of at least two of the following conditions: type 2 diabetes, ischaemic heart disease and stroke. We studied 269,197 employed UK Biobank participants free of cardiometabolic disease (CMD) at baseline. Weekly working hours were analysed in five categories, with 35-40 h/week as reference. Cox models assessed incident first CMD (FCMD), CMM and all-cause mortality. Multistate models assessed progression from no CMD to FCMD and from FCMD to CMM, with death possible from each state. Models were adjusted for demographic, socioeconomic, occupational and family-history factors. Estimates were pooled across 50 multiply imputed datasets. Within the disease observation window, 25,190 participants developed FCMD and 2,824 developed CMM. Working ≥55 h/week was associated with FCMD (hazard ratio [HR] 1.117, 95% confidence interval [CI] 1.057-1.180). Incident CMM from baseline was associated with 41-48 h/week (1.128, 1.010-1.260) and 49-54 h/week (1.205, 1.042-1.393); the estimate for ≥55 h/week was 1.144 (0.973-1.346). For FCMD-to-CMM progression, the corresponding HR were 1.141 (1.021-1.274), 1.129 (0.976-1.306) and 1.093 (0.929-1.286). Spline analyses supported overall associations with FCMD and incident CMM from baseline (both P<0.001), but not a clear association with FCMD-to-CMM progression (P=0.083). Long working hours were associated with first CMD onset and incident CMM in some working-hour groups; FCMD-to-CMM progression showed no clear increasing gradient. These findings support considering working time in cardiometabolic risk assessment while distinguishing initial disease development from subsequent progression.
中文摘要:长工作时间与心血管疾病代谢疾病累积之间的关联尚不明确。本研究将心血管疾病代谢多病共存定义为至少存在以下两种情况:2型糖尿病、缺血性心脏病和中风。我们分析了英国生物样本库中269,197名基线时无心血管疾病代谢疾病的受雇参与者。每周工作时间分为五类,以35至40小时为参照组。Cox模型评估了首次心血管疾病代谢疾病的发生、心血管疾病代谢多病共存及全因死亡率。多状态模型评估了从无心血管疾病代谢疾病到首次心血管疾病代谢疾病,以及从首次心血管疾病代谢疾病到心血管疾病代谢多病共存的进展过程,各状态均可能发生死亡。模型调整了人口统计学、社会经济、职业和家庭史因素。估计值在50个多重插补数据集中进行汇总。在疾病观察窗口内,25,190名参与者发展为首次心血管疾病代谢疾病,2,824名参与者发展为心血管疾病代谢多病共存。每周工作55小时及以上与首次心血管疾病代谢疾病的发生相关(风险比1.117,95%置信区间1.057至1.180)。基线时心血管疾病代谢多病共存的发生与工作41至48小时(1.128,1.010至1.260)和49至54小时(1.205,1.042至1.393)相关;工作55小时及以上的估计值为1.144(0.973至1.346)。从首次心血管疾病代谢疾病到心血管疾病代谢多病共存的进展中,相应的风险比分别为1.141(1.021至1.274)、1.129(0.976至1.306)和1.093(0.929至1.286)。样条分析支持首次心血管疾病代谢疾病发生及基线时心血管疾病代谢多病共存发生的总体关联(均P小于0.001),但未发现从首次心血管疾病代谢疾病到心血管疾病代谢多病共存进展的明确关联(P等于0.083)。长工作时间与某些工作时长组别的首次心血管疾病代谢疾病发生及心血管疾病代谢多病共存发生相关;首次心血管疾病代谢疾病到心血管疾病代谢多病共存的进展未显示明确的递增梯度。这些发现支持在心血管疾病代谢风险评估中考虑工作时间,同时区分初始疾病发展与后续进展。
Nonobstructive hypertrophic cardiomyopathy (nHCM), defined as hypertrophic cardiomyopathy without left ventricular outflow tract obstruction, remains challenging to treat because of its heterogeneous pathophysiology. This study evaluated the safety and efficacy of transapical beating-heart septal myectomy in patients with symptomatic nHCM. Patients with symptomatic, drug-refractory nHCM were prospectively enrolled to undergo transapical beating-heart septal myectomy through a left minithoracotomy. Under real-time transesophageal echocardiographic guidance, septal myectomy was tailored to relieve systolic cavity obliteration and mid-to-apical ventricular obstruction and to enlarge the left ventricular cavity. The primary end point was procedural success at 6 to 12 months postoperatively, defined as fulfillment of all prespecified criteria compared with baseline: ≥1-class improvement in New York Heart Association functional class, ≥10-point increase in Kansas City Cardiomyopathy Questionnaire score, ≥10-mL increase in stroke volume, and normal or grade I diastolic function. Between January 2023 and January 2025, 97 consecutive eligible patients with nHCM underwent transapical beating-heart septal myectomy at Tongji Hospital. At postoperative 6 to 12 months, procedural success was achieved in 87.6%. Specifically, New York Heart Association functional class I increased from 0% at baseline to 93.8% at follow-up, the median Kansas City Cardiomyopathy Questionnaire score improved from 64 (interquartile range, 56-69) to 87 (interquartile range, 82-92; P<0.001), the stroke volume increased from 53.5 mL (interquartile range, 41.0-66.6 mL) to 70.8 mL (interquartile range, 61.3-82.3 mL; P<0.001), and normal or grade I diastolic function increased from 65.6% to 97.9%. Among patients who underwent paired cardiopulmonary exercise testing (n=58), peak oxygen uptake increased by 1.1±2.9 mL/kg/min (P=0.008). In an exploratory, hypothesis-generating analysis of 12 patients with paired 13N-ammonia positron emission tomography, coronary flow reserve increased from 1.8±0.3 to 2.0±0.4 (P=0.034). Adverse events included mitral valve injury (n=1) and ventricular septal perforation (n=1), the latter resulting in 1 postoperative death. Transapical beating-heart septal myectomy was associated with favorable left ventricular geometric remodeling and meaningful improvements in symptoms, health status, and functional capacity in selected patients with symptomatic nHCM. Being a potential therapeutic option for a previously difficult-to-treat population, it warrants further evaluation in controlled, multicenter studies. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05648825.
中文摘要:无梗阻型肥厚型心肌病(nHCM)定义为无左室流出道梗阻的肥厚型心肌病,因其病理生理机制异质性,治疗仍具挑战性。本研究评估了经心尖跳动心脏室间隔切除术在症状性 nHCM 患者中的安全性和有效性。对具有症状且药物难治性的 nHCM 患者进行前瞻性入组,通过左侧小切口行经心尖跳动心脏室间隔切除术。在实时经食道超声心动图引导下,定制化切除室间隔以缓解收缩期腔室 obliteration 和中部至心尖部室梗阻,并扩大左室腔。主要终点为术后 6 至 12 个月的手术成功率,定义为与基线相比满足所有预设标准:纽约心脏病协会(NYHA)功能分级改善≥1级,堪萨斯城心肌病问卷(KCCQ)评分增加≥10分,每搏输出量增加≥10 mL,且舒张功能正常或为 I 级。2023 年 1 月至 2025 年 1 月期间,同济医院共有 97 名符合条件的 nHCM 患者接受了经心尖跳动心脏室间隔切除术。术后 6 至 12 个月时,手术成功率为 87.6%。具体而言,NYHA 功能分级 I 级从基线的 0% 增至随访期的 93.8%,KCCQ 中位数评分从 64(四分位距 56-69)改善至 87(四分位距 82-92;P<0.001),每搏输出量从 53.5 mL(四分位距 41.0-66.6 mL)增至 70.8 mL(四分位距 61.3-82.3 mL;P<0.001),正常或 I 级舒张功能比例从 65.6% 增至 97.9%。在接受配对心肺运动试验的患者中(n=58),峰值摄氧量增加 1.1±2.9 mL/kg/min(P=0.008)。在对 12 名接受配对 13N-氨正电子发射断层扫描患者的探索性假设生成分析中,冠状动脉血流储备从 1.8±0.3 增至 2.0±0.4(P=0.034)。不良事件包括二尖瓣损伤(n=1)和室间隔穿孔(n=1),后者导致 1 例术后死亡。经心尖跳动心脏室间隔切除术与左室几何重构的有利改变以及症状、健康状况和功能能力的显著改善相关,适用于部分症状性 nHCM 患者。作为此前难治人群的一种潜在治疗选择,值得在对照性多中心研究中进一步评估。URL: https://www.clinicaltrials.gov; Unique identifier: NCT05648825.
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with an increased risk of stroke, heart failure, mortality, and reduced quality of life. Although catheter ablation is the most widely used rhythm control strategy, its efficacy is limited in patients with non-paroxysmal atrial fibrillation and large left atria. To address this therapeutic gap, surgical approaches, including minimally invasive ablation, hybrid epicardial-endocardial strategies, and left atrial appendage exclusion, have continued to evolve. In this review, we focus on recent evidence to guide clinical decision-making on patient selection, advances in minimally invasive surgical and hybrid techniques, left atrial appendage exclusion, and postoperative anticoagulation management. Minimally invasive standalone Cox-Maze IV procedure and hybrid epicardial-endocardial ablation have demonstrated superior long-term freedom from atrial tachyarrhythmias compared with thoracoscopic epicardial surgical ablation or catheter ablation alone. Five-year arrhythmia-free survival has approached 85% to 95% in experienced centers after the Cox-Maze IV procedure and approximately 60% to 70% after hybrid ablation, compared with 35% to 45% after thoracoscopic epicardial ablation and 30% to 35% after single catheter ablation alone. Surgical left atrial appendage exclusion performed at the time of ablation may further reduce thromboembolic risk, although the optimal strategy for postprocedural anticoagulation remains uncertain. Careful patient selection remains essential, with atrial fibrillation type, duration, left atrial size, and previous treatment failure known to be key predictors of procedural success. As surgical techniques and supporting evidence continue to grow, standalone surgical ablation may assume a more important role in the contemporary management of atrial fibrillation, particularly for patients with advanced disease who are unlikely to achieve durable rhythm control with catheter ablation alone.
中文摘要:心房颤动是最常见的持续性心脏心律失常,与卒中、心力衰竭风险增加、死亡率升高及生活质量下降相关。尽管导管消融是最广泛使用的节律控制策略,但其在非阵发性心房颤动和左心房扩大患者中的疗效有限。为弥补这一治疗缺口,包括微创消融、杂交心外膜-心内膜策略以及左心耳闭合在内的外科方法不断演进。本综述聚焦于近期证据,以指导患者选择的临床决策、微创手术与杂交技术的进展、左心耳闭合及术后抗凝管理。与单独经胸镜心外膜外科消融或导管消融相比,独立的微创Cox-Maze IV术和杂交心外膜-心内膜消融显示出更优越的长期心房快速性心律失常无复发性。在经验丰富的中心,Cox-Maze IV术后五年无心律失常生存率接近85%至95%,杂交消融后约为60%至70%,而经胸镜心外膜消融后为35%至45%,单独导管消融后为30%至35%。在消融同时进行的左心耳闭合可进一步降低血栓栓塞风险,尽管术后抗凝的最佳策略仍不确定。谨慎的患者选择仍然至关重要,心房颤动类型、持续时间、左心房大小及既往治疗失败已知是手术成功的关键预测因素。随着外科技术和支持证据的不断增长,独立外科消融可能在当代心房颤动管理中发挥更重要的作用,特别是对于单靠导管消融难以实现持久节律控制的晚期疾病患者。
Frailty is associated with worse outcomes after coronary artery bypass grafting (CABG). However, the comparative effectiveness of off-pump CABG (OPCAB) versus on-pump CABG (ONCAB) in prefrail and frail patients remains uncertain. This multicenter, randomized, open-label trial enrolled patients ≥60 years of age classified as prefrail or frail, randomized 1:1, between January 2018 and December 2024. The primary outcome was a 30-day composite of death, myocardial infarction, stroke, renal failure, acute respiratory distress syndrome, or reoperation for bleeding. Secondary outcomes included ventilation time, intensive care unit and hospital stay, transfusion requirements, completeness of revascularization, surgical wound infection at 30 days, and neurocognitive function preoperatively and at 1 year. Analyses followed the intention-to-treat principle; relative risks with 95% CIs were estimated. A total of 508 patients were included (OPCAB, n=258; ONCAB, n=250; median age, 68 years [interquartile range, 65.0-73]; 30.5% female). The primary composite outcome occurred in 28 patients receiving OPCAB (10.9%) and 40 patients receiving ONCAB (16.0%; relative risk, 1.47 [95% CI, 0.94-2.31]; P=0.09). Surgical wound infection was more frequent with ONCAB (20 [8.0%] versus 9 [3.5%]; P=0.04). No significant differences were observed in neurocognitive or quality of life outcomes at 1 year. Estimated 1-year survival probabilities were 96.1% and 92.8% in the OPCAB and ONCAB groups, respectively (P=0.099). In prefrail and frail patients undergoing CABG, OPCAB and ONCAB resulted in similar rates of the primary composite outcome. No significant differences between OPCAB and ONCAB were found in neurocognitive outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02338947.
中文摘要:衰弱与冠状动脉旁路移植术(CABG)后不良预后相关。然而,体外循环下CABG(OPCAB)与体外循环外CABG(ONCAB)在预衰弱及衰弱患者中的比较疗效仍不明确。本研究是一项多中心、随机、开放标签试验,于2018年1月至2024年12月期间招募年龄≥60岁且被分类为预衰弱或衰弱的患者,按1:1比例随机分组。主要终点为30天内死亡、心肌梗死、卒中、肾衰竭、急性呼吸窘迫综合征或因出血再次手术的复合结局。次要终点包括通气时间、重症监护室及住院天数、输血需求、血运重建的完全性、30天时手术伤口感染以及术前和1年时的神经认知功能。分析遵循意向性治疗原则;估算相对风险及95%置信区间(CI)。共纳入508名患者(OPCAB组n=258,ONCAB组n=250;中位年龄68岁[四分位距65.0-73];女性占30.5%)。接受OPCAB的28名患者(10.9%)和接受ONCAB的40名患者(16.0%)出现主要复合结局(相对风险1.47[95%CI 0.94-2.31];P=0.09)。ONCAB组的手术伤口感染发生率更高(20例[8.0%]对比9例[3.5%];P=0.04)。在1年时,神经认知或生活质量方面未观察到显著差异。OPCAB组和ONCAB组的估计1年生存率分别为96.1%和92.8%(P=0.099)。在进行CABG的预衰弱及衰弱患者中,OPCAB与ONCAB的主要复合结局发生率相似。OPCAB与ONCAB在神经认知结局方面未发现显著差异。URL: https://www.clinicaltrials.gov; 唯一标识符: NCT02338947。
Among 3695 matched pairs with same-date emergency department contact, retinal artery occlusion was associated with lower brain imaging use (77.3% versus 91.7%) and slightly higher cervical imaging use (81.7% versus 79.2%) than transient ischemic attack.
中文摘要:在3695对具有相同日期急诊就诊记录的匹配队列中,视网膜动脉阻塞患者接受脑部影像检查的比例低于短暂性脑缺血发作患者(77.3%对比91.7%),而颈部影像检查的使用率略高(81.7%对比79.2%)。
People with peripheral artery disease (PAD) are often misdiagnosed or diagnosed late and, even after diagnosis, are undertreated with both pharmacologic and invasive therapies. The disease is associated with an increased risk of mortality, myocardial infarction, stroke, other vascular disease, limb loss, and reduced quality of life. Although the risks and long-term management of PAD are well documented, these risks are acutely magnified when PAD exists as a comorbidity in patients hospitalized for other cardiovascular or medical conditions. Procedures requiring vascular access for the treatment of acute myocardial infarction, cardiogenic shock, or valvular heart disease, as well as procedures for the treatment of the patient's underlying PAD, require special consideration in patients with PAD. Familiarity with the use and placement of mechanical circulatory support in patients with PAD, as well as the management of recent endovascular or surgical vascular interventions, is essential for providing appropriate care in the acute care setting.
中文摘要:外周动脉疾病患者常被误诊或诊断延迟,即使确诊后,在药物和介入治疗方面也存在治疗不足的问题。该疾病与死亡率增加、心肌梗死、卒中、其他血管疾病、肢体丧失及生活质量下降的风险升高相关。尽管外周动脉疾病的长期风险和管理已有充分记载,但当其作为合并症存在于因其他心血管或内科疾病住院的患者中时,这些风险会急剧放大。为治疗急性心肌梗死、心源性休克或瓣膜性心脏病而需进行血管通路操作,以及针对患者基础外周动脉疾病的治疗操作,均需在患有外周动脉疾病的患者中予以特别考量。熟悉机械循环支持在外周动脉疾病患者中的应用与置入,以及近期血管内或外科血管干预的管理,对于在急性医疗环境中提供适当护理至关重要。
Nighttime light exposure has emerged as a potential risk factor for cardiovascular disease (CVD). However, its impact on cardiac structure and function remains unknown. This population-based cohort study included 11 071 UK Biobank participants who wore a wrist-worn accelerometer with an integrated light sensor for 7 days between 2013 and 2015 (baseline) and had subsequent cardiovascular magnetic resonance (CMR) imaging 3 years later. Nighttime light exposure >3 lux was estimated, and its dose-response relationships with CMR phenotypes were examined using generalized linear regression models. Associations of nighttime light exposure with incident CVD outcomes and mortality were examined using Cox models (n = 73 286). After multivariable adjustment, high (vs none) nighttime light exposure >3 lux was associated with left ventricular (LV) concentric hypertrophy and subclinical functional decline, including 2.4% (95% confidence interval 1.6%, 3.1%) greater LV mass indexed to height1.7, 1.5% (1.0%, 2.0%) greater mean wall thickness, and 1.9% (1.1%, 2.7%) lower myocardial contraction fraction. Nighttime light exposure was also associated with impaired myocardial deformation, including lower absolute global LV circumferential [-2.7% (-3.7%, -1.7%)], radial [-2.9% (-3.9%, -1.8%)], and longitudinal strain [-2.8% (-3.9%, -1.7%)] indices. Adverse associations were also observed for the right ventricle, including 0.9% (0.1%, 1.8%) greater end-diastolic and 1.6% (0.5%, 2.8%) greater end-systolic volumes indexed, and for the left atrium, including 2.3% (0.7%, 3.9%) greater maximum volume indexed and 1.1% (0.3%, 1.9%) lower ejection fraction. All associations exhibited linear dose-response relationships, with most partly mediated by shorter sleep duration (proportion mediated: 24%-49%). During 8-10 years of follow-up, participants with high (vs none) nighttime light exposure had 29% (12%, 49%) higher risk of heart failure, 15% (4%, 27%) higher risk of atrial fibrillation, 24% (7%, 44%) higher risk of myocardial infarction, 33% (11%, 59%) higher risk of stroke, and 26% (5%, 52%) higher risk of CVD mortality. Greater nighttime light exposure was associated with adverse cardiac remodelling and subclinical functional decline across multiple chambers, statistically mediated by shorter sleep duration. These findings provide potential mechanistic insights into how nighttime light exposure may elevate CVD risk and highlight dark nights and adequate sleep for cardiovascular health.
中文摘要:夜间光照暴露已成为心血管疾病的风险因素,但其对心脏结构与功能的影响尚不明确。本研究为基于人群的队列研究,纳入2013至2015年间佩戴集成光传感器腕式加速度计7天的11071名UK Biobank参与者作为基线,并在3年后进行心血管磁共振成像。研究估算夜间光照暴露大于3勒克斯的情况,并使用广义线性回归模型分析其与心血管磁共振表型的剂量反应关系。使用Cox模型分析夜间光照暴露与心血管疾病结局及死亡率的关联(n=73286)。多变量调整后,高(相较于无)夜间光照暴露大于3勒克斯与左心室向心性肥厚及亚临床功能减退相关,包括左心室质量指数增加2.4%,平均壁厚度增加1.5%,心肌收缩分数降低1.9%。夜间光照暴露还与心肌变形受损相关,表现为左心室整体圆周应变、径向应变和纵向应变绝对值降低。右心室也观察到不良关联,包括舒张末期容积指数增加0.9%,收缩末期容积指数增加1.6%;左心房则表现为最大容积指数增加2.3%,射血分数降低1.1%。所有关联均呈现线性剂量反应关系,大部分部分由睡眠时间缩短介导(介导比例24%-49%)。在8至10年的随访期间,高夜间光照暴露参与者相较于无暴露者,心力衰竭风险高29%,心房颤动风险高15%,心肌梗死风险高24%,卒中风险高33%,心血管疾病死亡率风险高26%。较大的夜间光照暴露与多心室的不良心脏重构及亚临床功能减退相关,统计学上由睡眠时间缩短介导。这些发现为夜间光照暴露如何增加心血管疾病风险提供了潜在机制见解,并强调了黑暗夜晚和充足睡眠对心血管健康的重要性。
Generalised myasthenia gravis (gMG) significantly affects physical functioning and emotional wellbeing. Many patients with gMG report a disconnect between their lived experience and physicians' perceptions of disease impact, which may impact treatment priorities and shared decision-making. We assessed patient-physician concordance on perceived gMG burden and explored factors contributing to perceptual gaps. Across five European countries (France, Germany, Italy, Spain, UK), 167 adult patients with gMG and their treating physicians (n = 24) independently completed online surveys assessing the perceived impact of gMG on physical functioning and emotional wellbeing, using 0-100 visual analogue scales (VAS). Discordance was defined as an absolute VAS score difference of ≥ 20 points. Additionally, 25 patients and 25 physicians participated in semi-structured qualitative interviews exploring lived experiences, consultation dynamics, and treatment decision-making. VAS score agreement was assessed using intraclass correlation coefficient (ICC) and Bland-Altman analysis; qualitative interviews were analysed thematically. Overall, mean patient and physician VAS scores were similar for physical functioning (57.9 vs 59.6, p = 0.20) and emotional wellbeing (58.7 vs 61.0, p = 0.09), with "substantial" concordance in 81% of patient-physician pairs (ICC: ~ 0.7). Conversely, 19% of patient-physician pairs demonstrated clear discordance, with physicians either over- or underestimating burden. Notably, even among concordant pairs, up to one fifth reported score differences approaching the discordance threshold, reflecting subtle, but potentially meaningful, misalignment. Qualitative insights suggested that short consultations, under-recognition of fluctuating symptoms, and blind spots regarding psychosocial impacts may contribute to perceptual gaps. Despite overall broad patient-physician concordance of VAS scores, meaningful misalignment in perceived gMG burden persists. Qualitative insights highlighted perceptual gaps that may be driven by limited consultation time and under-addressed psychosocial needs. Incorporating structured, symptom-focused dialogue alongside standard assessments may improve recognition of disease burden and support patient-centred gMG management.
中文摘要:重症肌无力(gMG)显著影响患者的躯体功能与情绪健康。许多gMG患者报告其生活体验与医生对疾病影响的认知之间存在脱节,这可能影响治疗优先级和共同决策。本研究评估了欧洲五国(法国、德国、意大利、西班牙、英国)167名成年gMG患者与其主治医生(共24名)在感知gMG对躯体功能和情绪健康影响方面的一致性,并探索导致认知差距的因素。患者和医生独立完成了在线调查,使用0-100视觉模拟量表(VAS)评估疾病影响。不一致性定义为绝对VAS得分差异≥20分。此外,25名患者和25名医生参与了半结构化定性访谈,探讨生活体验、就诊动态和治疗决策。采用组内相关系数(ICC)和Bland-Altman分析评估VAS得分一致性;对定性访谈进行主题分析。总体而言,患者和医生的躯体功能平均VAS得分相似(57.9 vs 59.6,p=0.20),情绪健康得分也相似(58.7 vs 61.0,p=0.09),81%的患者-医生配对表现出“实质性”一致性(ICC约0.7)。相反,19%的患者-医生配对显示出明显的不一致性,医生要么高估要么低估疾病负担。值得注意的是,即使在一致的配对中,多达五分之一的报告得分差异接近不一致阈值,反映了微妙但可能具有意义的错位。定性见解表明,简短的就诊时间、对波动性症状的识别不足以及对心理社会影响的盲点可能导致认知差距。尽管VAS得分总体呈现广泛的一致性,但感知gMG负担的意义性错位仍然存在。定性见解突出了由有限就诊时间和未充分解决的心理社会需求驱动的感知差距。将结构化的以症状为中心的对话与标准评估相结合,可能有助于提高对疾病负担的认识并支持以患者为中心的gMG管理。
Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis.
Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0-12.0) and 14.0 days (interquartile range, 10.0-20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33-5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33-4.48]), female sex (HR, 1.78 [95% CI, 1.00-3.16]), and age (HR per year, 1.04 [95% CI, 1.00-1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64-4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76-3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20-3.01]), and age (HR per year, 1.06 [95% CI, 1.03-1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02329327.
中文摘要:与常规治疗相比,Andexanet可减少急性因子Xa抑制剂相关颅内出血的血肿扩大,但伴随血栓事件风险。本研究汇总接受Andexanet治疗的试验参与者数据以确定血栓事件的基线预测因素。对ANNEXA-I和ANNEXA-4试验中接受Andexanet治疗的成人参与者进行二次分析,这些参与者患有急性危及生命的出血且正在使用FXa抑制剂。采用分层Cox比例风险模型考察基线变量与动脉或所有血栓事件及死亡率的关联。采用以动脉事件为时间依赖性协变量的分层Cox回归模型,在调整临床协变量后考察动脉事件与死亡率的关联。741名参与者(平均年龄78.5岁;男性占54.5%)中,593人(80.0%)患有颅内出血,109人(14.7%)患有胃肠道出血。77名(10.4%)参与者发生≥1次血栓事件,147名(19.8%)死亡。随机分组后动脉和静脉血栓栓塞事件的中位发生时间分别为3.5天(四分位距2.0-12.0)和14.0天(四分位距10.0-20.0)。未发现基线因素与所有血栓事件相关。动脉血栓事件与既往心肌梗死(风险比HR 2.64 [95% CI 1.33-5.26])、高剂量资格(HR 2.44 [95% CI 1.33-4.48])、女性性别(HR 1.78 [95% CI 1.00-3.16])和年龄(每年HR 1.04 [95% CI 1.00-1.08])相关。死亡率与动脉血栓事件(HR 2.68 [95% CI 1.64-4.36])、既往充血性心力衰竭(HR 2.53 [95% CI 1.76-3.63])、颅内出血或脑室内出血(HR 1.90 [95% CI 1.20-3.01])和年龄(每年HR 1.06 [95% CI 1.03-1.08])相关。随机分组后启动抗凝治疗与血栓事件减少相关。在FXa抑制剂相关出血且接受Andexanet治疗的患者中,基线因素与动脉血栓事件相关并可用于指导治疗决策。启动抗凝治疗可减少血栓事件的发生。
基础研究 (6篇)
Mitochondria are central hubs of intracellular Ca2+ signaling, sensing, integrating, and responding to cytosolic Ca2+ transients through tightly regulated uptake and efflux pathways. Despite its fundamental role in cellular physiology, the mechanisms by which mitochondrial Ca2+ signaling contributes to tissue-specific pathologies remain poorly understood. Disruption of this ancient and ubiquitous process can lead to various disease phenotypes, including neurological disorders, stroke, heart failure, diabetes, and liver disease. This review highlights how extensive heterogeneity in the molecular composition, regulation, and spatial organization of mitochondrial Ca2+ signaling machinery underlies these pleiotropic outcomes. Physiological insights are examined alongside systems-level approaches, such as comparative genomics, evolutionary analyses, and protein-protein interaction mapping, to reveal context-specific architectures of mitochondrial Ca2+ signaling. Collectively, these advances provide a framework for understanding how mitochondrial Ca2+ uptake and efflux pathways are tailored to organ-specific functions and vulnerabilities.
中文摘要:线粒体是细胞内钙离子信号传导的核心枢纽,通过严格调控的摄取和流出途径感知、整合并响应胞质钙瞬变。尽管其在细胞生理中发挥基础作用,但线粒体钙信号传导导致组织特异性病理机制尚不明确。这种古老且普遍存在的过程紊乱可导致多种疾病表型,包括神经系统疾病、中风、心力衰竭、糖尿病和肝病。本综述强调了线粒体钙信号传导机器在分子组成、调控和空间组织上的广泛异质性如何导致这些多效性结果。结合比较基因组学、进化分析和蛋白质相互作用图谱等系统水平方法,深入探讨了生理见解,以揭示线粒体钙信号传导的上下文特异性架构。这些进展共同提供了一个框架,用于理解线粒体钙摄取和流出途径如何适应器官特异性功能和易感性。
Hemorrhagic transformation (HT) remains a life-threatening complication after acute ischemic stroke (AIS), yet no active predictive tool is available for early risk assessment. Herein, we develop an integrated triplex electrochemical aptasensing platform for the parallel and simultaneous quantification of three HT-associated biomarkers-matrix metalloproteinase-9 (MMP-9), fibronectin (FN), and plasminogen activator inhibitor-1 (PAI-1). The system enables parallel detection by inserting three independent screen-printed carbon electrodes (SPCEs) into a multi-channel electrochemical workstation, each functionalized with a distinct aptamer, allowing simultaneous quantification of MMP-9, FN, and PAI-1 within 30 min. Each SPCE is modified with a conductive polypyrrole/poly(3,4-ethylenedioxythiophene):polystyrene sulfonate/polyvinyl alcohol hydrogel and gold nanoparticles, followed by immobilization of specific thiolated aptamers via Au-S bonds. Upon target binding, aptamer conformational changes induce a concentration-dependent decrease in differential pulse voltammetry current. The sensor achieves ultralow detection limits of 4.04 fg/mL, 0.30 fg/mL, and 2.79 fg/mL for MMP-9, FN, and PAI-1, respectively, with a total assay time of 30 min. Clinical validation using plasma from 12 AIS patients demonstrates excellent agreement with enzyme-linked immunosorbent assay (mean bias <10%) and high reproducibility (RSD <5%). This work presents the first electrochemical aptasensor for FN and PAI-1 detection and provides a clinically validated, point-of-care-compatible platform for personalized HT risk prediction in thrombolytic therapy.
中文摘要:出血性转化(HT)仍是急性缺血性卒中(AIS)后危及生命的并发症,目前尚缺乏用于早期风险评估的主动预测工具。本研究开发了一种集成三重复电化学适配体传感平台,用于平行同时定量三种与HT相关的生物标志物:基质金属蛋白酶9(MMP-9)、纤维连接蛋白(FN)和纤溶酶原激活物抑制剂1(PAI-1)。该系统通过在多通道电化学工作站中插入三个独立的丝网印刷碳电极(SPCEs)实现并行检测,每个电极修饰有不同的适配体,从而在30分钟内同时定量MMP-9、FN和PAI-1。每个SPCE均涂覆导电聚吡咯/聚(3,4-乙撑二氧噻吩):聚苯乙烯磺酸/聚乙烯醇水凝胶及金纳米颗粒,并通过Au-S键固定特异性硫醇化适配体。靶标结合后,适配体构象变化导致差分脉冲伏安法电流呈浓度依赖性降低。该传感器对MMP-9、FN和PAI-1的检测限分别低至4.04 fg/mL、0.30 fg/mL和2.79 fg/mL,总检测时间为30分钟。利用12名AIS患者的血浆进行临床验证,结果显示与酶联免疫吸附测定法(ELISA)具有良好的一致性(平均偏差<10%)和高重现性(RSD <5%)。本研究首次报道了用于FN和PAI-1检测的电化学适配体传感器,并提供了一个经临床验证、适用于床旁检测的平台,用于溶栓治疗中个性化的HT风险预测。
Alcohol-related cardiovascular risk is being fundamentally reappraised. Observational associations suggesting cardioprotection with light-to-moderate drinking have been challenged by contemporary cohort analyses, Mendelian-randomization studies, biomarker-informed investigations, and updated public-health guidance. Uncertainty nevertheless persists at very low exposure levels and for selected coronary or all-cause outcomes. Alcohol is therefore best viewed as a dose-, pattern-, and host-dependent cardiovascular stressor. Acute or binge drinking, sustained heavy intake, chronic intake with episodic binges, and withdrawal produce overlapping but distinct phenotypes, including hypertension, atrial fibrillation, ventricular arrhythmias, sudden death, alcohol-associated cardiomyopathy, heart failure, stroke, and vascular disease. A systems-cardiology framework is presented in which direct myocardial injury, electrical instability, haemodynamic and autonomic stress, vascular and microvascular dysfunction, and disrupted inter-organ signalling interact. Ethanol and acetaldehyde toxicity, redox imbalance, microbial and inflammatory mediators, neurohumoral activation, and metabolic or electrolyte disturbances can impair endothelial signalling, mitochondrial energetics, excitation-contraction coupling, electrical stability, and repair. Pathway dominance varies across exposure patterns and susceptible hosts; coronary microvascular dysfunction may represent a convergence pathway rather than an obligatory mediator. Cumulative injury can diminish perfusion, contractile, electrical, autonomic, and exercise reserve. Alcohol-related cardiovascular ageing is proposed as a unifying cumulative phenotype encompassing mitochondrial dysfunction, oxidative and nitrative stress, inflammageing, senescence, impaired repair, circadian and epigenetic dysregulation, fibrosis, and ventriculo-arterial uncoupling, although direct human evidence remains incomplete. Age, biological sex, genetics, comorbidities, sleep-circadian disruption, nutrition, medications, and polysubstance misuse may modify pathway dominance and reversibility. Structured exposure assessment and alcohol reduction or abstinence, when indicated, are actionable components of cardiovascular prevention and care.
中文摘要:酒精相关的心血管风险正经历根本性的重新评估。提示轻度至中度饮酒具有心脏保护作用的观察性关联,已受到当代队列分析、孟德尔随机化研究、生物标志物导向调查以及更新后的公共卫生指南的挑战。然而,在极低暴露水平及特定冠状动脉或全因结局方面仍存在不确定性。因此,酒精最好被视为一种剂量、模式和宿主依赖的心血管应激源。急性或暴饮、持续大量摄入、慢性摄入伴间歇性暴饮以及戒断反应会产生重叠但独特的表型,包括高血压、心房颤动、室性心律失常、猝死、酒精相关性心肌病、心力衰竭、中风和血管疾病。本文提出了一种系统心脏病学框架,其中直接心肌损伤、电不稳定、血流动力学与自主神经应激、血管及微血管功能障碍以及器官间信号传导紊乱相互作用。乙醇与乙醛毒性、氧化还原失衡、微生物与炎症介质、神经体液激活以及代谢或电解质紊乱可损害内皮信号传导、线粒体能量代谢、兴奋收缩耦联、电稳定性及修复能力。通路优势因暴露模式和易感宿主而异;冠状动脉微血管功能障碍可能代表一种汇聚通路而非必然的中介因素。累积性损伤可降低灌注、收缩、电生理、自主神经及运动储备。酒精相关的心血管衰老被提出作为一种统一的累积表型,涵盖线粒体功能障碍、氧化与硝化应激、炎症衰老、细胞衰老、修复受损、昼夜节律与表观遗传失调、纤维化以及心室动脉解耦联,尽管直接的人类证据仍不完整。年龄、生物性别、遗传因素、合并症、睡眠昼夜节律紊乱、营养、药物及多物质滥用可能修饰通路优势及可逆性。结构化的暴露评估以及在有指征时减少或戒断酒精摄入,是心血管预防与护理中可操作的组成部分。
Ingestible capsules have garnered considerable attention due to their high gastrointestinal (GI) transitability and minimally invasive nature. However, constrained by pill-sized dimensions (approximately 2 to 4 cubic centimeters), current ingestible capsules face persistent challenges in achieving both controllable high mechanical output and sufficient onboard power delivery, limiting their capacity for effective in vivo therapeutic interventions. Here, we present a wirelessly powered ingestible electronic capsule that integrates programmable soft phase-change actuation within a rigid-soft architecture to enable programmable, high-output mechanical operations. Leveraging bidirectional thermoelectric regulation and guided rigid-soft coupling, the capsule delivers a peak force of 3.8 newtons and a volumetric stroke of ∼250 cubic millimeters within a confined geometry based on the phase-change actuation. To power this actuation, we implemented a compact wireless power transfer system that achieved a maximum load-received power per unit receiver-coil volume of 9.15 watts per cubic centimeter at a 5-centimeter transfer distance under the tested conditions. The structural adaptability of the soft actuator allows modular integration of functional end-effectors, supporting high-output tissue acquisition, site-directed delivery of model liquid or gel payloads, and active biofluid sampling under magnetic navigation. In vivo experiments in beagles demonstrated the feasibility of mechanical interventions in physiological environments. By overcoming the long-standing power and actuation constraints of capsule architecture, this work establishes a physical framework for high-output ingestible robotics and advances the development of minimally invasive robotic platforms for complex GI interventions.
中文摘要:可吞服胶囊因其高胃肠道通过性和微创特性而备受关注。然而,受限于药丸尺寸(约2至4立方厘米),现有可吞服胶囊在实现可控的高机械输出和充足的机载电力输送方面仍面临持续挑战,限制了其在体内有效治疗干预中的应用能力。本研究提出了一种无线供电的可吞服电子胶囊,该胶囊在刚性-柔性架构中集成了可编程的软相变驱动机制,以实现可编程、高输出的机械操作。利用双向热电调节和引导式刚柔耦合技术,该胶囊在受限几何空间内基于相变驱动提供了3.8牛顿的峰值力和约250立方毫米的体积行程。为驱动此动作,我们实施了一个紧凑的无线电力传输系统,在测试条件下,以5厘米传输距离实现了每单位接收线圈体积9.15瓦的最大负载接收功率。软执行器的结构适应性支持功能末端执行器的模块化集成,从而在磁导航支持下实现高输出组织获取、模型液体或凝胶载荷的定点递送以及主动生物流体采样。比格犬体内实验证明了机械干预在生理环境中的可行性。通过克服胶囊架构长期存在的电力和驱动限制,本研究为高输出可吞服机器人建立了物理框架,并推动了用于复杂胃肠道干预的微创机器人平台的发展。
Rehabilitation is an effective and reliable approach for promoting motor recovery after stroke. However, its efficacy decreases during the transition from the subacute to the chronic phase after stroke, posing a major barrier to complete functional recovery. This limited efficacy during the chronic phase is believed to result from declining neural plasticity. However, the molecular and cellular mechanisms regulating neural plasticity and its temporal changes after stroke remain unclear. To address this gap, we established a focal ischemic stroke mouse model that allows causal interrogation of the mechanisms responsible for the reduced efficacy of rehabilitation in the chronic phase. Using this model, we identified Lynx1, an endogenous negative allosteric modulator of nicotinic acetylcholine receptors, as a negative regulator of post-stroke neural plasticity. Lynx1 expression in layer 5 pyramidal neurons was transiently down-regulated and returned to normal levels in the peri-infarct area. Longitudinal intravital imaging revealed that Lynx1 suppression promoted synaptic clustering with increased dendritic spine turnover in the peri-infarct area, an emerging structural basis for memory formation. As anticipated, Lynx1 suppression improved spontaneous motor recovery and the efficacy of rehabilitation in the chronic phase after stroke. Furthermore, we developed a Lynx1-targeting antisense oligonucleotide and found that its administration during the chronic phase after stroke enhanced the efficacy of rehabilitation. These findings suggest that dendritic spine dynamics in the peri-infarct area are a key determinant of rehabilitation responsiveness through the regulation of clustered spine formation and that Lynx1 may represent a promising therapeutic target for augmenting dendritic plasticity after stroke.
中文摘要:康复是促进卒中后运动功能恢复的有效且可靠的方法。然而,其疗效在卒中从亚急性期向慢性期过渡时下降,这构成了实现完全功能恢复的主要障碍。这种在慢性期的有限疗效被认为源于神经可塑性的下降。然而,调控神经可塑性及其卒中后时间变化的分子和细胞机制仍不清楚。为弥补这一空白,我们建立了局灶性缺血性卒中小鼠模型,以因果性地探究导致慢性期康复疗效降低的机制。利用该模型,我们发现Lynx1(烟碱型乙酰胆碱受体的内源性负变构调节剂)是卒中后神经可塑性的负调控因子。在梗死周围区域,第5层锥体神经元中的Lynx1表达呈瞬时下调并恢复至正常水平。纵向活体成像显示,抑制Lynx1促进了梗死周围区域的突触簇形成,并增加了树突棘周转率,这是记忆形成的新兴结构基础。正如预期,抑制Lynx1改善了卒中后慢性期的自发运动康复和康复疗效。此外,我们开发了靶向Lynx1的反义寡核苷酸,发现其在卒中后慢性期给药可增强康复疗效。这些发现表明,梗死周围区域的树突棘动力学通过调控簇状棘的形成,是决定康复反应性的关键因素,且Lynx1可能代表一种增强卒中后神经可塑性的有前景的治疗靶点。
The development of advanced therapies for stroke, spinal cord injury, and neurodegenerative diseases-primary causes of death, disability and dementia-requires a comprehensive understanding of the interplay between excitotoxicity, aberrant neurotrophic-signalling, glial reactivity, and neuroinflammation. Recent evidence has identified the truncated neurotrophin receptor TrkB-T1 as a potential master regulator of these processes. TrkB-T1 levels increase after stroke whereas the pro-survival full-length isoform (TrkB-FL) decreases. Furthermore, stroke-induced excitotoxicity triggers TrkB-T1 regulated intramembrane proteolysis (RIP), which produces TrkB-T1-ICD, a poorly characterised fragment containing the receptor intracellular domain and a few transmembrane amino acids. This study investigated whether the TrkB-T1 intracellular domain intrinsically contributes to neurotoxicity, reactive gliosis, and neuroinflammation. Our results predict that TrkB-T1 RIP generates a nuclear localization signal in TrkB-T1-ICD that might support nuclear translocation and injury-induced transcriptional regulation in neurons undergoing excitotoxicity. Using cell-penetrating peptides (CPPs), we generated a TrkB-T1-ICD mimetic peptide (Bio-LTT1Ct) containing the TrkB-T1 intracellular region. Bio-LTT1Ct translocated to the nucleus of neurons and astrocytes, provoking cell death and inducing early transcriptional changes in neurons, resembling those triggered by excitotoxicity. In vivo, intranasally administrated Bio-LTT1Ct was brain-permeable and distributed within cortical neurons and astrocytes across both hemispheres. Notably, Bio-LTT1Ct administration was sufficient to promote TrkB isoform imbalance, glial reactivity, and acquisition of proinflammatory profiles, all considered stroke hallmarks. In conclusion, these results imply that TrkB-T1 RIP might be a central mechanism of ischaemic damage and identify the receptor's intracellular region as sufficient to recapitulate stroke-like effects, marking this pathological mechanism as a critical target for therapy.
中文摘要:开发针对卒中、脊髓损伤和神经退行性疾病的先进疗法,需要全面理解兴奋性毒性、异常神经营养信号传导、胶质细胞反应性和神经炎症之间的相互作用。近期证据表明,截短的神经营养因子受体TrkB-T1可能是这些过程的主要调节因子。卒中后TrkB-T1水平升高,而促进存活的全长亚型(TrkB-FL)降低。此外,卒中诱导的兴奋性毒性触发TrkB-T1调控的膜内蛋白水解(RIP),产生TrkB-T1-ICD,这是一种含有受体胞内结构域和少量跨膜氨基酸的特征尚不明确的片段。本研究探讨了TrkB-T1胞内结构域是否内在性地促进神经毒性、反应性胶质增生和神经炎症。我们的结果预测,TrkB-T1 RIP在TrkB-T1-ICD中产生核定位信号,可能支持经历兴奋性毒性的神经元中的核易位和损伤诱导的转录调控。利用细胞穿透肽(CPPs),我们生成了包含TrkB-T1胞内区域的TrkB-T1-ICD模拟肽(Bio-LTT1Ct)。Bio-LTT1Ct易位至神经元和星形胶质细胞的细胞核,引发细胞死亡并诱导神经元早期转录变化,类似于兴奋性毒性触发的变化。在体内,鼻内给药的Bio-LTT1Ct具有脑渗透性,分布在双侧大脑皮层的神经元和星形胶质细胞中。值得注意的是,Bio-LTT1Ct的给药足以促进TrkB亚型失衡、胶质细胞反应性和促炎表型的获得,这些均被视为卒中的标志。总之,这些结果暗示TrkB-T1 RIP可能是缺血损伤的核心机制,并确定受体的胞内区域足以重现卒中样效应,将该病理机制标记为治疗的关键靶点。
3神经肌肉病与周围神经 (7篇)
临床研究 (3篇)
The primary goal of randomized controlled trials is typically to understand the impact of a treatment on an outcome(s) of interest. Randomization is a critical design component for making these types of cause-and-effect inferences, as it ensures balance between the treatment groups in terms of both known and unknown confounders (factors related to both exposure and outcome), which can introduce bias when imbalanced across exposure (treatment) groups. When comparing treatment groups in the primary analysis of a randomized controlled trial, participants are typically included with the group to which they were randomized, following a framework referred to as intention to treat (ITT). ITT intentionally does not account for postrandomization events (eg, protocol nonadherence) in order to maintain the integrity of the randomization. There are other non-ITT frameworks for randomized controlled trial analyses, including the common per-protocol, as-treated, and modified ITT analyses. This article summarizes ITT and non-ITT frameworks and the research questions which they address, discusses their trade-offs, and provides information about operationalizing randomized controlled trial analyses, including discussion of the available topical guidance, considerations for conducting analyses in the face of missing data, and evolving statistical methods for non-ITT analyses.
中文摘要:随机对照试验的主要目标通常是了解治疗对特定结局的影响。随机化是进行因果推断的关键设计要素,因为它能确保治疗组在已知和未知的混杂因素方面保持平衡,这些因素若在各暴露(治疗)组间分布不均可能会引入偏倚。在进行随机对照试验的主要分析时,参与者通常按其被随机分配的组别纳入分析,这种框架被称为意向性治疗(ITT)。ITT有意不纳入随机化后的事件(例如方案依从性差),以维持随机化的完整性。随机对照试验的分析还存在其他非ITT框架,包括常见的符合方案集、按实际治疗和修改的ITT分析。本文总结了ITT和非ITT框架及其所解决的研究问题,讨论了它们的权衡利弊,并提供了关于实施随机对照试验分析的信息,包括对现有相关指南的讨论、处理缺失数据时的考量以及针对非ITT分析的演变统计方法。
The occurrence of peripheral neuropathy (PN) in dermatomyositis (DM) is poorly characterized. To characterize the occurrence, clinical patterns, and electrophysiological features of PN in patients with DM. This cohort study used data from a single academic center database of patients with DM who were enrolled between July 2008 and December 2025. Patients with PN were identified through medical record review of problem lists, encounter diagnoses, and clinical notes. PN diagnosis was established by clinical examination, nerve conduction study (NCS), or skin punch biopsy. Patients with PN that was associated with diabetes or prediabetes, vitamin deficiency, infection, trauma, nerve compression, radiculopathy, or neurotoxic medication were excluded. DM subtype, autoantibody positivity, and systemic manifestations. Main outcomes were frequency and clinical/electrophysiological characteristics of PN among patients with DM. Among 640 patients with DM (median [IQR] age, 60 [40.8-70.0] years; 546 [85.3%] female; 94 [14.7%] male), 120 (18.8%) had clinically documented PN (median [IQR] age, 60 [50.5-70.8] years; 104 [86.7%] female; 16 [13.3%] male), ascertained at a median (IQR) of 3 (1-9) years after DM diagnosis. Patients with PN were significantly more likely to have classic DM than patients without PN (75 of 120 [62.5%] vs 269 of 520 [51.7%]; P = .03). Patients with PN had higher rates of arthralgia (95 of 120 [79.2%] vs 93 of 511 [18.2%]; P < .001) and Raynaud syndrome (67 of 120 [55.8%] vs 198 of 511 [38.7%]; P < .001), and lower myositis-specific antibody positivity (28 of 104 patients [26.9%] vs 112 of 295 [38.0%]; P = .04), than patients without PN. NCS was performed in 61 patients, with positive findings in 39 patients (63.9%) and negative findings in 22 patients (36.1%). Mixed sensory-motor polyneuropathy was most common (23 of 39 patients [58.9%]), followed by pure sensory neuropathy (12 of 39 patients [30.8%]), with axonal features predominating (37 of 39 patients [94.9%]) over demyelinating features (2 of 39 patients [5.1%]). Small-fiber neuropathy was biopsy-confirmed in 4 patients (3.3%) and clinically suspected without biopsy confirmation in 16 patients (13.3%). In this cohort study, clinically documented PN was identified in nearly one-fifth of the DM cohort after exclusion of secondary causes and was associated with classic DM subtype and higher rates of arthralgia and Raynaud syndrome. The predominance of axonal over demyelinating patterns on NCS suggests inflammatory axonal injury as one possible mechanism, though other causes cannot be excluded. These findings suggest PN is an underrecognized systemic association of DM warranting heightened clinical awareness and further mechanistic investigation.
中文摘要:皮肌炎(DM)患者并发周围神经病变(PN)的发生情况尚不明确。本研究旨在描述DM患者中PN的发生率、临床模式及电生理特征。该队列研究使用了2008年7月至2025年12月期间在单一学术中心数据库入组的DM患者数据。通过病历问题列表、就诊诊断和临床笔记审查识别PN患者。PN的诊断依据临床检查、神经传导研究(NCS)或皮肤穿刺活检确立。排除了与糖尿病或糖尿病前期、维生素缺乏、感染、创伤、神经压迫、神经根病或神经毒性药物相关的PN患者。记录了DM亚型、自身抗体阳性及系统表现。主要结局指标为DM患者中PN的发生率及临床/电生理特征。在640名DM患者(中位年龄[IQR]60[40.8-70.0]岁;女性546名[85.3%];男性94名[14.7%])中,120名(18.8%)有临床记录的PN(中位年龄[IQR]60[50.5-70.8]岁;女性104名[86.7%];男性16名[13.3%]),在DM诊断后中位时间(IQR)3(1-9)年确诊。与无PN患者相比,有PN患者更可能患有经典DM亚型(120例中的75例[62.5%] vs 520例中的269例[51.7%];P=.03)。与无PN患者相比,有PN患者关节痛发生率更高(120例中的95例[79.2%] vs 511例中的93例[18.2%];P<.001)和雷诺综合征发生率更高(120例中的67例[55.8%] vs 511例中的198例[38.7%];P<.001),肌炎特异性自身抗体阳性率较低(104例患者中的28例[26.9%] vs 295例中的112例[38.0%];P=.04)。对61名患者进行了NCS,其中39名(63.9%)结果阳性,22名(36.1%)结果阴性。混合感觉运动性多发性神经病最常见(39例中的23例[58.9%]),其次是纯感觉性神经病(39例中的12例[30.8%]),轴索特征占主导地位(39例中的37例[94.9%])而非脱髓鞘特征(39例中的2例[5.1%])。小纤维神经病在4名患者(3.3%)中经活检证实,另有16名患者(13.3%)临床疑似但未获活检确认。在该队列研究中,排除继发性原因后,近五分之一的DM队列被识别出有临床记录的PN,且与经典DM亚型及更高的关节痛和雷诺综合征发生率相关。NCS中轴索特征优于脱髓鞘特征提示炎症性轴索损伤可能是机制之一,尽管不能排除其他原因。这些发现表明PN是DM的一种未被充分认识的全身性关联,需要提高临床意识并进行进一步的机制研究。
Preclinical evidence suggests synergy between poly-ADP-ribose inhibitors and camptothecin chemotherapy. We tested the talazoparib and irinotecan combination (TI) in the neoadjuvant setting in the I-SPY2 trial in patients with HER2-negative locally advanced breast cancer. I-SPY2 is a phase II platform trial for stage 2/3 early breast cancer at high risk of recurrence. Participants were adaptively randomized to one of several experimental neoadjuvant therapies or control based on receptor subtypes defined by hormone receptor (HR), HER2 status, and MammaPrint risk (MP1, MP2). The primary endpoint was pathological complete response (pCR). Treatments 'graduate' if/when they achieve an 85% Bayesian probability of success in a subtype-specific phase III trial. Only HER2-negative patients were eligible for randomization to the TI arm. All patients received weekly paclitaxel for 12 weeks, followed by doxorubicin/cyclophosphamide and surgery. Participants randomized to the TI arm received daily oral talazoparib and irinotecan infusions every other week. Pathway-specific biomarkers were assessed for response prediction. The combination of talazoparib and irinotecan failed to graduate from the I-SPY2 trial, with a 19% modeled posterior probability of pCR in the TI arm compared with 20% in the control arm among all patients with HER2-negative breast cancer. The most common adverse events were neutropenia and anemia in the TI arm and neuropathy and fatigue in the control arm. pCR rates were highest in patients with germline Breast Cancer Gene 1 or 2 (BRCA1/2) mutations receiving TI (pCR rate 50%) and in those with tumors expressing a DNA repair deficiency signature. TI will not be further explored as a combination given lack of improved efficacy over control (paclitaxel) for neoadjuvant treatment in patients with HER2-negative breast cancer. pCR rates were highest (50%) among patients with germline BRCA1/2 mutations, likely due to the efficacy of talazoparib alone. Further combinations could be explored in patients with HER2-negative breast cancer and a germline BRCA1/2 or PALB2 mutation.
中文摘要:临床前证据表明聚ADP核糖聚合酶抑制剂与喜树碱类化疗药物存在协同作用。我们在I-SPY2试验中测试了talazoparib和伊立替康联合方案(TI)在HER2阴性局部晚期乳腺癌新辅助治疗中的应用。I-SPY2是一项针对具有高复发风险的II/III期早期乳腺癌患者的II期平台试验。参与者根据激素受体、HER2状态及MammaPrint风险评分进行亚型分类,并自适应随机分配至多种实验性新辅助治疗方案或对照组。主要终点为病理完全缓解率(pCR)。当某方案在特定亚型的III期试验中达到85%的成功贝叶斯概率时,该方案将被视为通过。仅HER2阴性患者有资格被随机分配至TI组。所有患者均接受每周一次紫杉醇治疗12周,随后进行多柔比星/环磷酰胺治疗及手术。TI组参与者每日口服talazoparib并每两周接受一次伊立替康输注。研究评估了通路特异性生物标志物以预测疗效。Talazoparib与伊立替康的联合方案未能在I-SPY2试验中通过,在所有HER2阴性乳腺癌患者中,TI组的模型后验pCR概率为19%,而对照组为20%。TI组最常见的不良事件为中性粒细胞减少和贫血,对照组则为神经病变和疲劳。接受TI治疗的胚系BRCA1/2突变患者pCR率最高(50%),表达DNA修复缺陷特征的患者亦然。鉴于该联合方案在HER2阴性乳腺癌新辅助治疗中未显示出优于对照组的疗效,不再进一步探索其联合应用。pCR率在携带胚系BRCA1/2突变的患者中最高(50%),这可能与talazoparib单药的疗效有关。未来可在携带胚系BRCA1/2或PALB2突变的HER2阴性乳腺癌患者中探索其他联合方案。
基础研究 (4篇)
Microglial senescence is a candidate contributor to brain ageing and Alzheimer's disease, but its identification and therapeutic tractability remain contested. Activation, lysosomal expansion, lipid accumulation and dystrophic morphology do not independently establish senescence. This review critically examines how uncertainty in state identification affects mechanistic interpretation and natural-product evaluation. Genetic perturbation, human induced pluripotent stem cell models and pharmacological studies connect mitochondrial proteotoxic stress, impaired autophagy, DNA damage and sustained inflammatory signalling with senescence-associated microglial phenotypes. Disease-associated and senescence-associated microglial populations are not interchangeable. Delphinidin, andrographolide, resveratrol, honokiol, rosmarinic acid and cycloastragenol reduce senescence-associated readouts in selected experimental systems. Current evidence mainly supports prevention or phenotype modulation; selective microglial senolysis, durable reversal and senescence-dependent cognitive rescue remain unestablished. Functional assessment requires substrate specificity: impaired harmful-substrate disposal can coexist with excessive synaptic engulfment. Translation requires achievable unbound brain exposure, treatment after phenotype establishment and models relevant to human ageing. Circulating inflammatory-marker changes alone cannot demonstrate drug action within microglia or modification of their senescence-associated state. Small, uncontrolled senolytic trials support the feasibility of treatment administration and preliminary pharmacological assessment, but do not establish cognitive efficacy or selective action on senescent microglia. Progress depends on convergent state identification, delayed intervention, lineage-resolved causal experiments and exposure-matched pharmacology. Natural products remain useful mechanistic probes and potential therapeutic leads whose value should be judged by restoration of protective microglial functions and neural outcomes, rather than marker suppression alone.
中文摘要:小胶质细胞衰老是大脑衰老和阿尔茨海默病的潜在致病因素,但其鉴定和治疗可行性仍存在争议。激活、溶酶体扩张、脂质积累和萎缩形态不能独立确立衰老状态。本综述批判性地审视了状态识别的不确定性如何影响机制解释和天然产物评估。遗传扰动、人诱导多能干细胞模型和药理学研究将线粒体蛋白毒性应激、自噬受损、DNA损伤和持续性炎症信号与衰老相关的小胶质细胞表型联系起来。疾病相关和小胶质细胞衰老相关群体不可互换。德尔菲尼定、穿心莲内酯、白藜芦醇、厚朴酚、迷迭香酸和环阿斯特酮在选定的实验系统中降低了衰老相关的读数。现有证据主要支持预防或表型调节;选择性小胶质细胞衰老清除、持久逆转和衰老依赖的认知挽救仍未确立。功能评估需要底物特异性:有害底物清除受损可与过度突触吞噬共存。转化研究要求实现非结合脑暴露量,在表型建立后进行治疗并使用与人类衰老相关的模型。循环炎症标志物的变化本身不能证明药物在小胶质细胞内的作用或其衰老相关状态的改变。小型无对照的衰老清除试验支持治疗给药和初步药理学评估的可行性,但未确立认知疗效或对衰老小胶质细胞的选择性作用。进展依赖于收敛的状态识别、延迟干预、谱系解析的因果实验和暴露匹配的毒理学研究。天然产物仍是有用的机制探针和潜在的治疗先导物,其价值应根据保护性小胶质细胞功能和神经结局的恢复来评判,而非仅凭标志物抑制。
α-Aminoadipic semialdehyde synthase (AASS) catalyzes the first two steps of lysine catabolism. Inherited metabolic disorders affecting enzymes downstream of AASS, including α-aminoadipic semialdehyde dehydrogenase (ALDH7A1) deficiency, which causes pyridoxine-dependent epilepsy, and glutaric aciduria type I, cause accumulation of potentially neurotoxic lysine-derived metabolites. Current therapies incompletely prevent metabolite accumulation and neurological sequelae. We evaluated whether hepatic AASS silencing could reduce conversion of lysine into downstream metabolites. Antisense oligonucleotides and small interfering RNAs targeting AASS reduced disease-associated metabolites in patient-derived cells from individuals with ALDH7A1 deficiency and glutaric aciduria type I. Hepatocyte-selective delivery, enabled by N-acetylgalactosamine conjugation, achieved >90% liver-specific Aass knockdown in wild-type and Aldh7a1 knockout mice, with sustained protein suppression and reduced accumulation of downstream lysine-derived metabolites. These findings support further evaluation of oligonucleotide-mediated AASS silencing, including liver-directed delivery, as a substrate reduction strategy for ALDH7A1 deficiency and glutaric aciduria type I.
中文摘要:α-氨基己二酸半醛合成酶(AASS)催化赖氨酸分解代谢的前两步。影响AASS下游酶的遗传性代谢疾病,包括引起吡哆醇依赖性癫痫的α-氨基己二酸半醛脱氢酶(ALDH7A1)缺乏症和戊二酸尿症I型,会导致潜在神经毒性的赖氨酸衍生代谢物积累。现有疗法无法完全阻止代谢物积累及神经系统后遗症。我们评估了肝脏AASS沉默是否能减少赖氨酸向下游代谢物的转化。靶向AASS的反义寡核苷酸和小干扰RNA在来自ALDH7A1缺乏症和戊二酸尿症I型个体的患者来源细胞中降低了疾病相关代谢物。通过N-乙酰半乳糖胺偶联实现的肝细胞选择性递送,在野生型和Aldh7a1敲除小鼠中实现了超过90%的肝脏特异性Aass敲低,并维持了蛋白质抑制及下游赖氨酸衍生代谢物积累的减少。这些发现支持进一步评估寡核苷酸介导的AASS沉默(包括肝脏定向递送)作为ALDH7A1缺乏症和戊二酸尿症I型的底物减少策略。
Peripheral myeloid cells are key regulators of systemic inflammation and promising targets for immune intervention in Alzheimer's disease (AD). However, selective in vivo small interfering RNA (siRNA) delivery to these cells remains challenging because conventional lipid nanoparticles often exhibit predominant hepatic accumulation and usually require ligand or antibody modification for immune-cell targeting. Here, we report a structure-engineered lipid-mineral nanoparticle platform, termed MCP, for ligand-free myeloid RNA interference (RNAi) delivery. MCP integrates a calcium phosphate mineral phase with a phosphatidic acid-enriched lipid interface, enabling efficient siRNA incorporation. The Ca2+-lipid cooperative architecture promoted macropinocytosis-dependent uptake and preferential siRNA delivery to peripheral myeloid cells in vivo, particularly Ly6Chigh monocytes and macrophages, with enhanced delivery under AD-associated inflammatory conditions. Systemic delivery of MCP carrying siRNA against triggering receptor expressed on myeloid cells 1 (TREM1) attenuated neuroinflammatory and neurodegenerative pathology in an AD mouse model, supporting peripheral myeloid reprogramming as a route to modulate central nervous system (CNS) disease progression. Notably, MCP also achieved efficient TREM1 silencing in AD patient-derived peripheral blood mononuclear cells (PBMCs) and restored TREM1 expression toward healthy-control levels. This work establishes a structure-driven, ligand-free lipid-mineral RNAi platform for peripheral immune intervention in AD.
中文摘要:外周髓系细胞是系统性炎症的关键调节因子,也是阿尔茨海默病免疫干预的有前景靶点。然而,选择性体内小干扰RNA递送至这些细胞仍具挑战性,因为传统脂质纳米颗粒常表现出主要的肝脏蓄积,且通常需要配体或抗体修饰以实现免疫细胞靶向。本研究报道了一种结构工程化的脂质-矿物纳米颗粒平台MCP,用于无配体髓系RNA干扰递送。MCP将磷酸钙矿物相与富含磷脂酸的脂质界面相结合,实现了高效的siRNA包载。Ca2+-脂质协同架构促进了依赖巨胞饮作用的摄取,并在体内优先将siRNA递送至外周髓系细胞,特别是Ly6Chigh单核细胞和巨噬细胞,且在阿尔茨海默病相关的炎症条件下递送效率增强。系统性递送携带针对髓系细胞表达触发受体1的siRNA的MCP,减轻了阿尔茨海默病小鼠模型中的神经炎症和神经退行性病理,支持通过外周髓系重编程来调节中枢神经系统疾病进展。值得注意的是,MCP还在阿尔茨海默病患者来源的外周血单个核细胞中实现了高效的TREM1沉默,并将TREM1表达恢复至健康对照水平。这项工作建立了一种结构驱动、无配体的脂质-矿物RNAi平台,用于阿尔茨海默病的外周免疫干预。
The rapid and discriminative detection of multiple pathogens is crucial for effective disease control, yet remains a significant challenge for point-of-care testing (POCT). Herein, we report a novel probe design strategy-Antiphasic Arctangent-Arccotangent (AAA) probes-for kinetically orthogonal, low-crosstalk multiplex detection in a single closed tube via loop-mediated isothermal amplification (LAMP). The AAA probe system comprises two kinetically complementary probes: the Arctangent Probe (ATP), a stem-loop probe that yields a rising fluorescence signal, and the Arccotangent Probe (ACP), a guanine-quenched linear probe that produces a falling fluorescence signal. Their inherently antiphasic kinetic trajectories effectively reduce false positives arising from nonspecific amplification. This system requires no additional enzymes or complex operations, preserving the simplicity of conventional LAMP. As a proof of concept, we demonstrated its utility by simultaneously detecting Japanese encephalitis virus (JEV) and Plasmodium vivax (P. vivax), two representative mosquito-borne pathogens, with high specificity and a sensitivity of 5 copies/μL. The assay performed robustly with clinical samples and in complex matrices (e.g., serum, tissue homogenates). Beyond the specific duplex detection, the AAA probe principle establishes a general framework for designing orthogonal probe sets, offering a promising and versatile strategy for multiplex nucleic acid detection in resource-limited settings.
中文摘要:多重病原体的快速鉴别检测对疾病控制至关重要,但仍是即时检测(POCT)的重大挑战。本文报道了一种新型探针设计策略-反相反正切-反余切(AAA)探针-用于通过环介导等温扩增(LAMP)在单个封闭管中实现动力学正交、低交叉干扰的多重检测。AAA探针系统包含两个动力学互补的探针:反正切探针(ATP),一种茎环探针,产生上升荧光信号;以及反余切探针(ACP),一种鸟嘌呤淬灭线性探针,产生下降荧光信号。其内在的反相动力学轨迹有效减少了由非特异性扩增引起的假阳性。该系统无需额外酶或复杂操作,保留了传统LAMP的简便性。作为概念验证,我们展示了其在同时检测日本脑炎病毒(JEV)和间日疟原虫(P. vivax)这两种代表性蚊媒病原体方面的实用性,具有高特异性和5 copies/μL的灵敏度。该检测在临床样本和复杂基质(如血清、组织匀浆)中表现稳健。除特定双联检测外,AAA探针原理建立了设计正交探针集的通用框架,为资源有限环境下的多重核酸检测提供了一种有前景且通用的策略。
4神经遗传/影像与基础转化 (5篇)
基础研究 (5篇)
Neuronal dysfunction in Alzheimer's disease (AD) is increasingly linked to dynamic and context-dependent alterations in intracellular signaling. However, how these changes drive progressive neurodegeneration and divergent neuronal outcomes remains poorly understood. Integrative analyses across independent human single-nucleus RNA sequencing datasets were performed to identify neuronal factors consistently altered in AD. Signal transducer and activator of transcription 4 (STAT4) distribution in different cell types was further validated using a mouse single-cell RNA sequencing dataset and experimental models. Functions of STAT4 were examined in human SH-SY5Y cells, mouse HT22 neuronal cells, mouse primary neurons, and inducible systems. In vivo effects were assessed in 3×Tg-AD and wild-type mice with AAV-mediated Stat4 modulation and pharmacological ERK inhibition. Multi-omics approaches, including RNA-seq, Cut&Tag, and RIP-seq, were used to explore downstream regulatory mechanisms. Integrative analyses identified STAT4 as a neuron-enriched factor consistently reduced in AD neurons. STAT4 supported neuronal integrity and synaptic homeostasis under basal conditions. Inducible restoration of STAT4 expression exerted divergent effects in a time-dependent manner, with early adaptive responses transitioning to later oxidative stress- and apoptosis-associated changes. Sustained STAT4 restoration induced oxidative stress, apoptosis-related signaling, and tau protein-related alterations, which were attenuated by ERK inhibition. In contrast, the beneficial outputs, including reduced Aβ burden and improved synaptic and neuronal markers, were preserved despite ERK inhibition. Parallel analyses in wild-type mice showed a delayed trajectory, indicating disease-context-dependent modulation. STAT4 was further associated with coordinated signaling networks and hnRNPK-related regulatory complexes. These findings define a time- and context-dependent signaling framework in which STAT4-associated outputs progressively shift toward maladaptive, ERK-sensitive responses in AD. Selective constraint of the late-stage signaling imbalance may attenuate the pathological outcomes while preserving the beneficial effects, providing a potential strategy for context-specific therapeutic intervention.
中文摘要:阿尔茨海默病(AD)中的神经元功能障碍日益被认为与细胞内信号动态且依赖情境的改变有关。然而,这些改变如何驱动进行性神经退行性变及不同的神经元结局仍不清楚。通过对独立的人类单核RNA测序数据集进行整合分析,鉴定出在AD神经元中持续改变的神经元因子。利用小鼠单细胞RNA测序数据集和实验模型进一步验证了信号转导与转录激活因子4(STAT4)在不同细胞类型中的分布。在人类SH-SY5Y细胞、小鼠HT22神经元细胞、小鼠原代神经元及诱导系统中检查了STAT4的功能。通过AAV介导的Stat4调节和药理学ERK抑制,在3×Tg-AD和小鼠野生型模型中评估了体内效应。采用包括RNA-seq、Cut&Tag和RIP-seq在内的多组学方法探索下游调控机制。整合分析确定STAT4为一种神经元富集因子,其在AD神经元中持续减少。STAT4在基础条件下支持神经元完整性和突触稳态。诱导性恢复STAT4表达以时间依赖的方式产生不同的效应,早期适应性反应逐渐转变为后期与氧化应激和凋亡相关的改变。持续的STAT4恢复诱导了氧化应激、凋亡相关信号及tau蛋白相关改变,这些改变可被ERK抑制所减轻。相比之下,尽管存在ERK抑制,包括减少Aβ负荷和改善突触及神经元标志物在内的有益输出得以保留。对野生型小鼠的平行分析显示轨迹延迟,表明疾病情境依赖性的调节。STAT4进一步与协调的信号网络及hnRNPK相关调控复合物有关。这些发现定义了一种时间与情境依赖性的信号框架,其中STAT4相关的输出在AD中逐渐转向适应不良且对ERK敏感的响应。选择性限制晚期信号失衡可能在保留有益效应的同时减轻病理结局,为情境特异性治疗干预提供了一种潜在策略。
Alzheimer's disease (AD) arises from pathological interactions among diverse brain cell types, but cell-type-specific proteomic changes remain underexplored. Here, we present deep proteomic profiling of sorted or proximity-labeled brain cells from AD mouse models (5xFAD and AppNL-G-F) at multiple ages, quantifying 13,411 proteins in microglia, astrocytes, oligodendrocyte precursor cells, and neurons, with additional spatial information. We identified 3,028 differentially abundant proteins, most of which were absent in a bulk proteomic dataset, and constructed cell-type-specific networks to define functional modules and hub proteins. Comparison with transcriptomic data revealed that ∼30% of proteomic changes are RNA discordant. Further analyses uncovered cross-cell-type signaling proteins conserved in human AD brains, such as pleiotrophin (Ptn), which is transcriptionally enriched in astrocytes but accumulates in microglia. Importantly, recombinant PTN activates human induced microglia (iMG) cells. Thus, these findings provide a comprehensive cell-type-resolved proteomic atlas of AD models, highlighting novel intra- and intercellular signaling events.
中文摘要:阿尔茨海默病(AD)源于多种脑细胞类型之间的病理相互作用,但细胞特异性蛋白质组学变化仍未得到充分探索。本研究对多个年龄阶段的 AD 小鼠模型(5xFAD 和 AppNL-G-F)中分选或邻近标记的脑细胞进行了深度蛋白质组学分析,定量分析了小胶质细胞、星形胶质细胞、少突胶质细胞前体细胞和神经元中的 13,411 种蛋白质,并提供了额外的空间信息。我们鉴定出 3,028 种差异丰度蛋白质,其中大多数在批量蛋白质组数据集中不存在,并构建了细胞特异性网络以定义功能模块和枢纽蛋白。与转录组数据的比较显示,约 30% 的蛋白质组学变化存在 RNA 不一致性。进一步分析揭示了在人 AD 大脑中保守的跨细胞类型信号蛋白,例如在多形性神经营养因子(Ptn),其在星形胶质细胞中转录富集但在小胶质细胞中积累。重要的是,重组 PTN 可激活人诱导的小胶质细胞(iMG)。因此,这些发现提供了 AD 模型的全面细胞分辨率蛋白质组学图谱,突出了新的细胞内和细胞间信号事件。
Visual impairment is a common and clinically salient manifestation of Multiple Sclerosis (MS), yet pathology across visual system structures remains incompletely defined. Although the optic nerve, lateral geniculate nucleus, and visual cortex have been extensively studied, involvement of the superior colliculus (SC), a key visual processing hub, remains unclear. Here, we combined human postmortem tissue analysis with functional assessment and spatial mapping in the MS-relevant cuprizone (CPZ) mouse model to define how demyelination and secondary injury are organized within the SC. Postmortem SC tissue from donors with MS revealed myelin loss, including focal demyelinated lesions. In mice, CPZ impaired visual function and induced widespread SC demyelination without detectable neuronal loss or axonal degeneration. In male mice, although diffuse demyelination was accompanied by widespread microgliosis, atlas-based mapping uncovered a previously unrecognized spatial organization: a discrete high-microgliosis compartment with a stereotyped location and shape in every CPZ-treated mouse. This compartment did not correspond to canonical SC maps and was not explained by baseline microglial or myelin differences or by variability in local demyelination severity. Instead, high-microgliosis regions showed increased synaptic elimination, suggesting that secondary synaptic pathology may contribute to spatial organization of microgliosis beyond diffuse myelin loss alone. Prolonged CPZ exposure expanded the high-microgliosis compartment stereotypically, whereas withdrawal produced spatially ordered partial resolution with persistence of a high-microgliosis core and partial visual recovery. Former high-microgliosis territories showed partial restoration of synaptic density despite myelin recovery comparable to persistent high-microgliosis regions. In contrast, female CPZ-treated mice developed widespread SC demyelination and microgliosis without comparable compartmentalization, demonstrating sex-differential organization of microglial reactivity. Together, these findings identify the human SC as a site of demyelinating injury in MS and establish the CPZ-treated mouse SC as a sex-sensitive in vivo framework for investigating spatially patterned microglial reactivity, synaptic pathology, and incomplete resolution of microgliosis after demyelination.
中文摘要:视力障碍是多发性硬化症常见且具临床意义的表现,但视觉系统各结构中的病理机制尚不明确。尽管视神经、外侧膝状体和视觉皮层已被广泛研究,作为关键视觉处理枢纽的上丘受累情况仍不清楚。本研究结合人类死后组织分析与多发性硬化相关杯形毒素小鼠模型的功能评估及空间映射,旨在明确脱髓鞘及继发性损伤在上丘中的组织方式。来自多发性硬化症供体的上丘死后组织显示存在髓鞘丢失,包括局灶性脱髓鞘病灶。在小鼠中,杯形毒素损害了视觉功能并诱导广泛的上丘脱髓鞘,但未检测到神经元丢失或轴突退化。在雄性小鼠中,尽管弥漫性脱髓鞘伴随广泛的微胶质细胞增生,但基于图谱的映射揭示了一种此前未被认识的空间组织模式:在每个经处理的雄性小鼠中都存在一个位置固定、形状刻板的高微胶质细胞增生区。该区域不符合经典的上丘图谱,也不能由基线微胶质细胞或髓鞘差异或局部脱髓鞘严重程度变异来解释。相反,高微胶质细胞增生区域显示出突触消除增加,表明继发性突触病理可能超越单纯的弥漫性髓鞘丢失,对微胶质细胞增生的空间组织做出贡献。长期暴露于杯形毒素使该高微胶质细胞增生区刻板地扩大,而撤药后产生空间有序的部分缓解,表现为高微胶质细胞核心持续存在及部分视觉恢复。先前的高微胶质细胞区域在髓鞘恢复程度与持续高微胶质细胞区域相当的情况下,显示出突触密度的部分恢复。相比之下,雌性杯形毒素处理小鼠出现广泛的上丘脱髓鞘和微胶质细胞增生,但未表现出类似的区室化,证明了小胶质细胞反应性的性别差异组织方式。综上所述,这些发现确定了人类上丘是多发性硬化症中脱髓鞘损伤的部位,并建立了经处理的雄性小鼠上丘作为研究空间模式化小胶质细胞反应性、突触病理以及脱髓鞘后微胶质细胞增生不完全缓解的性别敏感体内框架。
Brain atrophy is a hallmark of multiple sclerosis (MS) and precedes clinical symptom onset. However, whether brain development and morphological measures contribute to MS susceptibility remains unclear. We investigated whether genetically determined brain imaging phenotypes are associated with MS risk. We applied causal inference approaches using genome-wide association study (GWAS) data for 170 heritable magnetic resonance imaging (MRI)-derived phenotypes from 39,691 United Kingdom (UK) Biobank participants and leveraged with MS susceptibility GWAS data from 14,802 MS patient and 26,703 controls. Generalized summary-data-based Mendelian randomization with HEIDI filtering was used to assess putative causal associations while accounting for horizontal pleiotropy, with orthogonal sensitivity analysis using 2-sample Mendelian randomization. Significant loci underwent functional annotation, Bayesian colocalization with brain expression quantitative trait loci, integration with single-nucleus RNA-sequencing data from MS postmortem tissue, and druggability assessment. False discovery rate adjustments were applied. Four MRI phenotypes were associated with MS susceptibility: cerebellar vermis VIIIa gray-matter volume, mean diffusivity of the right anterior corona radiata, intracellular volume fraction of the corpus callosum, and orientation dispersion index of the right external capsule. Functional analyses identified 120 candidate genes, including several within the complex 17q21.31 locus. Cell-type-specific Mendelian randomization identified higher genetically predicted PLEC expression in inhibitory neurons and microglia as associated with lower MS susceptibility. Differential gene expression analyses highlighted convergent dysregulation of MAPT, EGFR, and HBEGF, implicating neurodevelopmental, neurovascular, and autophagy-related pathways. Twenty-five candidate genes were identified as potentially druggable targets. Genetically determined brain structural traits are associated with MS susceptibility, supporting the concept that premorbid brain architecture contributes to disease vulnerability and highlighting potential therapeutic targets. ANN NEUROL 2026.
中文摘要:脑萎缩是多发性硬化(MS)的特征性表现,且先于临床症状出现。然而,大脑发育和形态学指标是否影响MS易感性尚不明确。本研究利用英国生物银行39691名参与者的170种遗传性磁共振成像(MRI)表型全基因组关联研究(GWAS)数据,结合包含14802例MS患者和26703例对照的MS易感性GWAS数据,探究遗传决定的脑影像表型与MS风险的关系。采用经HEIDI过滤的广义基于摘要数据的孟德尔随机化方法评估潜在因果关联,并校正水平多效性,同时使用两样本孟德尔随机化进行正交敏感性分析。对显著位点进行功能注释、与脑表达数量性状基因座的贝叶斯共定位、整合来自MS死后组织的单核RNA测序数据以及药物可及性评估,并应用错误发现率调整。结果显示四种MRI表型与MS易感性相关:小脑蚓部VIIIa灰质体积、右侧前辐射区平均扩散率、胼胝体内细胞积分数和右侧外囊方向色散指数。功能分析鉴定出120个候选基因,包括位于复杂17q21.31基因座内的多个基因。细胞类型特异性孟德尔随机化表明,抑制性神经元和小胶质细胞中遗传预测的PLEC表达升高与较低的MS易感性相关。差异基因表达分析突出了MAPT、EGFR和HBEGF的趋同失调,涉及神经发育、神经血管和自噬相关通路。鉴定出25个候选基因为潜在的可药物靶向靶点。遗传决定的脑结构特征与MS易感性相关,支持病前脑架构影响疾病脆弱性的概念,并突显了潜在的治疗靶点。ANN NEUROL 2026.
Parkinson's disease (PD), one of the most common neurodegenerative disorders, is characterized by mitochondrial dysfunction, neuroinflammation, and dopaminergic neuronal loss. Mitochondrial transplantation has emerged as a potential therapeutic strategy to treat various diseases with highly unmet needs. However, its application to brain diseases is limited by inefficient delivery across the blood-brain barrier (BBB). In this study, we engineered mitochondria to express a single-chain variable fragment against insulin-like growth factor 1 receptor on the outer mitochondrial membrane to enhance brain delivery. Surface engineering preserved mitochondrial functional integrity while significantly enhancing BBB transport in vitro. Following intravenous administration, human-specific mitochondrial DNA tracing demonstrated greater delivery of engineered mitochondria to the whole brain, striatum, and substantia nigra than naïve mitochondria. Functionally, they mitigated PD-relevant neurotoxin-induced damage, suppressed lipopolysaccharide-induced microglial activation and inflammation, and restored mitochondrial dysfunction. In a 6-hydroxydopamine-induced PD mouse model, engineered mitochondrial transplantation improved motor deficits, increased dopaminergic neuron survival, and reduced microgliosis, compared with naïve mitochondrial transplantation. Furthermore, engineered mitochondria promoted the expression of dopaminergic genes by activating nuclear receptor subfamily 4 group A member 2. Together, these findings demonstrate that engineered mitochondria represent a promising strategy to overcome BBB limitations and provide a novel therapeutic approach for PD.
中文摘要:帕金森病是一种最常见的神经退行性疾病,其特征为线粒体功能障碍、神经炎症和多巴胺能神经元丢失。线粒体移植已成为治疗多种高未满足需求疾病的潜在策略,但其在脑部疾病中的应用受限于跨越血脑屏障的低效递送。本研究通过在线粒体外膜表达针对胰岛素样生长因子1受体的单链可变片段来工程化改造线粒体,以增强脑部递送能力。表面工程在保持线粒体功能完整性的同时,显著增强了体外血脑屏障的转运效率。静脉注射后,人特异性线粒体DNA示踪显示,工程化线粒体在全脑、纹状体和黑质中的递送量均高于未改造线粒体。在功能上,它们减轻了帕金森病相关神经毒素诱导的损伤,抑制了脂多糖诱导的小胶质细胞激活和炎症,并恢复了线粒体功能障碍。在6-羟基多巴胺诱导的帕金森病小鼠模型中,与未改造线粒体移植相比,工程化线粒体移植改善了运动缺陷,增加了多巴胺能神经元的存活率,并减少了小胶质细胞增生。此外,工程化线粒体通过激活核受体亚家族4组A成员2促进了多巴胺能基因的表达。综上所述,这些发现表明工程化线粒体是克服血脑屏障限制的一种有前景的策略,并为帕金森病提供了一种新的治疗方法。
5癫痫 (4篇)
临床研究 (3篇)
Influenza A can cause encephalopathy or encephalitis, yet adult data are scarce and the two entities are seldom distinguished systematically. This small retrospective study of five adults explored the feasibility and limitations of classifying these complications with the International Encephalitis Consortium (IEC) 2013 criteria and describes their clinical, radiological, cerebrospinal fluid (CSF), and treatment characteristics. We retrospectively reviewed five consecutive adults admitted to a tertiary center with polymerase chain reaction (PCR)-confirmed influenza A and acute neurological symptoms, all evaluated with brain magnetic resonance imaging (MRI), lumbar puncture, and electroencephalography (EEG). Encephalitis was defined by the IEC 2013 criteria (altered mental status > 24 h plus ≥ 2 minor criteria of central nervous system (CNS) inflammation). Data were analyzed descriptively. Three patients met criteria for encephalitis and two for encephalopathy (four women; age 44-68 years). Respiratory influenza A PCR was positive and CSF PCR negative in all. CSF pleocytosis occurred in two patients, bilateral thalamic and subcortical white matter MRI hyperintensities in two, generalized EEG slowing in four, and focal status epilepticus in one. All received oseltamivir; three received high-dose methylprednisolone, two of whom also required intravenous immunoglobulin and plasma exchange. The categories overlapped substantially: EEG slowing and negative CSF PCR occurred in both, and treatment escalation followed clinical course rather than category, with the most intensive regimen required by one patient in each. At 3 months, three patients were asymptomatic and two, both with encephalitis and structural MRI lesions, had persistent deficits. In this small, hypothesis-generating study, IEC-based classification was feasible, but encephalitis and encephalopathy overlapped substantially and the distinction did not determine treatment. The main contribution lies in illustrating both the feasibility and limitations of criteria-based classification in adults with influenza A, rather than in establishing its clinical utility.
中文摘要:流感A型病毒可引起脑病或脑炎,但成人相关数据稀缺且这两类疾病很少被系统区分。本研究为一项针对五名成人的小型回顾性研究,旨在探讨依据国际脑炎联盟(IEC)2013年标准对这些并发症进行分类的可行性与局限性,并描述其临床、影像学、脑脊液(CSF)及治疗特征。我们回顾性分析了入住三级医疗中心的五名连续成人患者,这些患者经聚合酶链反应(PCR)确诊为流感A型感染并伴有急性神经系统症状,均接受了脑部磁共振成像(MRI)、腰椎穿刺和脑电图(EEG)评估。根据IEC 2013年标准定义脑炎(意识改变超过24小时且具备中枢神经系统炎症的至少两项次要标准)。数据采用描述性分析。结果显示三名患者符合脑炎标准,两名符合脑病标准(四名为女性,年龄44至68岁)。所有患者呼吸道流感A型PCR阳性而脑脊液PCR阴性。两名患者出现脑脊液白细胞增多,两名患者MRI显示双侧丘脑及皮层下白质高信号,四名患者脑电图显示广泛性慢波,一名患者出现局灶性癫痫持续状态。所有患者均接受奥司他韦治疗;三名患者接受大剂量甲泼尼龙治疗,其中两名还需静脉注射免疫球蛋白和血浆置换。这两类疾病存在显著重叠:脑电图慢波和脑脊液PCR阴性在两类患者中均可见,且治疗升级取决于临床病程而非分类结果,每类中各有一名患者接受了最密集的治疗方案。随访3个月时,三名患者无症状,两名脑炎患者(伴有结构性MRI病变)遗留持续性神经功能缺损。在这项生成假设的小型研究中,基于IEC标准的分类具有可行性,但脑炎与脑病存在显著重叠,且这种区分并未决定治疗方案。本研究的主要贡献在于阐明成人流感A型感染中基于标准分类的可行性与局限性,而非确立其临床效用。
In antiseizure medication clinical trials, a ≥ 50% reduction in seizure frequency is a relatively standard primary efficacy endpoint, but the real-world threshold for response perceived as clinically impactful for patients with tuberous sclerosis complex (TSC) is largely unassessed. We investigated this threshold in patients with TSC from the randomized controlled trial evaluating cannabidiol (CBD; Epidyolex® [EU]/Epidiolex® [USA]; ClinicalTrials.gov ID: NCT02544763). This post hoc analysis used receiver operating characteristics (ROC) to quantify thresholds at which monthly seizure frequency reduction could be deemed clinically important in pooled data from patients receiving 25 or 50 mg/kg/day CBD (n = 132) for 16 weeks. Reductions in seizure frequency were anchored to Caregiver Global Impression of Change (CGIC; caregiver-reported assessment tool) ratings of 'slightly improved' or better, or 'much improved' or better. Anchor-based methods and distribution-based methods were applied to determine the thresholds for a clinically important response and minimal clinically important difference, respectively. The best-fit ROC-derived threshold for a clinically important response associated with a CGIC of 'slightly improved' or better was a 33% reduction in seizure frequency; for 'much improved' or better, the threshold was a 52% reduction. Thresholds for the minimal clinically important difference, based on half standard deviation (standard error of the mean), were - 17.8% (- 19.5%) for a CGIC rating of 'slightly improved' or better, and - 17.2% (- 18.9%) for CGIC rating of 'much improved' or better. Spearman's correlation was 0.54 (P < 0.001). When anchored to a CGIC rating of 'slightly improved' or better, the threshold for a clinically important response in seizure reduction was 33%, suggesting that a cut-off of 50% may overlook patients who are achieving meaningful improvements in their overall condition, as perceived by their caregivers. This exploratory analysis may help physicians to ascertain the level of improvement that patients and caregivers perceive as beneficial in TSC, particularly when seizure reductions are < 50%. ClinicalTrials.gov ID: NCT02544763.
中文摘要:在抗癫痫药物临床试验中,发作频率降低≥50%是相对标准的疗效主要终点,但对于结节性硬化症(TSC)患者而言,被视为具有临床影响力的真实世界反应阈值尚未得到充分评估。本研究利用随机对照试验数据评估了大麻二酚(CBD;Epidyolex®[欧盟]/Epidiolex®[美国];ClinicalTrials.gov ID: NCT02544763)对TSC患者的影响,旨在确定这一阈值。该事后分析采用受试者工作特征(ROC)曲线,量化了每月发作频率降低幅度达到临床重要性的阈值,数据来源于接受25或50 mg/kg/天CBD治疗16周的患者汇总数据(n=132)。发作频率的降低以照护者全球印象改变量表(CGIC;照护者报告的评估工具)评分为锚点,即「轻微改善」及以上或「显著改善」及以上。研究分别应用基于锚点的方法和基于分布的方法来确定临床重要反应的阈值和最小临床重要差异。与CGIC评分「轻微改善」及以上相关的最佳拟合ROC衍生阈值为发作频率降低33%;对于「显著改善」及以上,该阈值为降低52%。基于半标准差(均值的标准误)的最小临床重要差异阈值为:CGIC评分「轻微改善」及以上为-17.8%(-19.5%),CGIC评分「显著改善」及以上为-17.2%(-18.9%)。Spearman相关系数为0.54(P < 0.001)。当以CGIC评分「轻微改善」及以上为锚点时,发作减少具有临床重要意义的阈值为33%,这表明将阈值设定为50%可能会忽视那些整体状况获得照护者所感知到的有意义改善的患者。这项探索性分析有助于医生确定TSC患者及照护者认为有益的改善水平,特别是在发作频率降低幅度小于50%的情况下。ClinicalTrials.gov ID: NCT02544763。
The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.
中文摘要:IDH1/2抑制剂维罗替尼在术后残留或复发的IDH1/2突变型2级胶质瘤中显示出疗效。然而,目前缺乏关于预测反应概率因素的知识。我们开展了一项前瞻性单中心研究,纳入54例接受维罗替尼治疗的IDH1/2突变型星形细胞瘤和IDH1/2突变型1p/19q共缺失型少突胶质细胞瘤(均为2级)。纵向评估了MRI反应(2D和3D)及癫痫结局。使用回归模型探索与反应相关的因素。中位随访时间为17.5个月,维罗替尼在MRI上诱导肿瘤进行性缩小,第6周期体积中位减少-12.2%,第12周期为-27.8%,第18周期为-55.5%。最佳体积反应中,完全缓解(CR)1例,部分缓解(PR)5例,微小缓解(MR)9例,疾病稳定(SD)31例,疾病进展(PD)7例。客观缓解率(ORR,即CR+PR+MR)为28%。18例伴有局灶性3级区域的患者的体积反应和ORR相似。基线有癫痫的12例患者中有9例(75%)实现了≥50%的发作减少或无发作。MRI反应与早期治疗启动及早期癫痫减少相关。维罗替尼总体耐受性良好,肝酶升高是主要不良事件。维罗替尼诱导了持续的肿瘤缩小和癫痫控制。早期治疗启动和早期癫痫减少与MRI反应相关。
基础研究 (1篇)
Brain somatic mutations are a major cause of epileptogenic focal cortical malformations. Hyaline astrocytic inclusions represent a rare neuropathological finding in epilepsy. We analyzed eight patients undergoing surgery for drug-resistant focal epilepsy associated with astrocytic inclusions, combining bulk and single-nucleus genomic analyses, cell-type-specific genetic profiling, neuropathological characterization, and electrophysiological recordings to establish genotype-neuropathology correlations. Microelectrode array recordings from cortical slices from one patient revealed spontaneous abnormal network activity in regions without astrocytic inclusions. Multilayered genomic analysis of surgical brain tissue, including single-nucleus sequencing, identified mosaic chromosome 1q copy-number gains in all eight cases, with chr1q tetrasomies confirmed in six. In four cases, the supernumerary chromosome 1q was of maternal origin, and long-read haplotyping in a patient-parent trio supported a novel mechanism of meiosis II chromosome missegregation. Chr1q gains were enriched in inclusion-bearing astrocytes, linking chromosomal aneuploidy to neuropathology. Finally, we developed a targeted sequencing panel enabling the detection of chr1q gains in surgical brain samples, including samples obtained from presurgical stereo-EEG electrodes. Together, these findings support postzygotic rescue of a maternal meiotic error in non-neural lineages as a mechanism of pathogenic brain mosaicism and define mosaic chr1q gain as a distinct cause of epilepsy.
中文摘要:脑体细胞突变是导致致痫性局灶性皮质发育不良的主要原因。透明胶质细胞包涵体是癫痫中罕见的神经病理发现。我们分析了八例接受药物难治性局灶性癫痫手术的患者,结合宏基因组和单核基因组分析、细胞类型特异性遗传谱系分析、神经病理学特征描述以及电生理记录,以建立基因型与神经病理学的相关性。来自一名患者皮质切片的微电极阵列记录显示,在无胶质细胞包涵体的区域存在自发的异常网络活动。对手术脑组织进行的多层基因组分析包括单核测序,在所有八例病例中均发现了嵌合染色体1q拷贝数增加,其中六例证实为chr1q四体。在四例病例中,多余的染色体1q来自母系,患者父母三联体的长读长单倍型分型支持了一种新的减数分裂II期染色体错误分离机制。Chr1q增益在含有包涵体的星形胶质细胞中富集,将染色体非整倍性与神经病理学联系起来。最后,我们开发了一种靶向测序面板,能够检测手术脑样本中的chr1q增益,包括术前立体脑电图电极获取的样本。综上所述,这些发现支持在有丝分裂后非神经谱系中对母系减数分裂错误的挽救作为致病性脑嵌合体的机制,并将嵌合chr1q增益定义为癫痫的一种独特原因。
6帕金森病与运动障碍 (4篇)
临床研究 (1篇)
The risk of Parkinson disease (PD) due to Agent Orange, the Vietnam War Era defoliant, is inferred from studies of agricultural pesticide exposure. Epidemiological work is currently lacking. To examine the association between Agent Orange exposure with incident cases of synucleinopathies including Parkinson disease, rapid eye movement (REM) sleep behavior disorder (RBD), and dementia with Lewy bodies (DLB) among US veterans. This was an electronic health record-based cohort study inclusive of medical records from January 1, 1999, to December 30, 2022. Veterans were followed up for a mean (SD) of 12.5 (7.0) years from the start of records. Analyses were conducted from July 2024 to July 2026. The setting was the US Department of Veterans Affairs and included US veterans who served during the Vietnam War Era (August 1964 to May 1975) were screened. Those with incomplete demographic data or prevalent synucleinopathies before or within 6 months of follow-up were excluded. Agent Orange defined by self-report. Direct or occupational exposure was defined by involvement in Operation Ranch Hand, Army Chemical Corps, and/or direct handling or spraying. Cumulative incidence of synucleinopathies was calculated adjusting for competing risk of death, age, traumatic brain injury, and frailty. After screening of 4 917 272 US veterans, 4 468 509 veterans (mean [SD] age, 60.6 [8] years; 4 380 139 male [98%]) were included in analyses. A total of 1 035 210 veterans (23.2%) had Agent Orange exposure; 7600 (0.2%) of these had direct or occupational exposure. Birth year, age at time 0 (start of records), sex, race, ethnicity, and smoking history were balanced among the exposed and unexposed groups with further adjustment for traumatic brain injury and frailty. Agent Orange exposure was associated with higher risk of PD (hazard ratio [HR], 1.44; 95% CI, 1.37-1.52), RBD (HR, 1.78; 95% CI, 1.68-1.89), and DLB (HR, 1.66; 95% CI, 1.32-2.09). Associations strengthened when enriched for direct or occupational exposure, including PD (HR, 1.99; 95% CI, 1.71-2.32) and RBD (HR, 2.25; 95% CI, 1.87-2.70). Results were robust to additional adjustment for traumatic brain injury, frailty, health care utilization, and multiple imputation. Sensitivity analyses indicated that substantial unmeasured confounding would be required to explain the observed associations. Results of this cohort study suggest that Agent Orange may be an independent risk factor for later development of PD and related conditions. This finding has implications for global policy change. Further studies are needed to understand the mechanism underlying this association, gene-toxin interactions, and whether there is a unique clinical phenotype to those exposed to Agent Orange.
中文摘要:橙剂作为越南战争时期的除草剂,其对帕金森病的风险通常基于农业农药暴露研究推断,目前尚缺乏流行病学证据。本研究旨在考察美国退伍军人中橙剂暴露与突触核蛋白病(包括帕金森病、快速眼动睡眠行为障碍和路易体痴呆)发病率之间的关联。这是一项基于电子健康记录的队列研究,纳入1999年1月1日至2022年12月30日的医疗记录。退伍军人从记录开始被平均随访12.5年(标准差7.0年)。分析于2024年7月至2026年7月进行。研究背景为美国退伍军人事务部,筛选了越南战争时期服役(1964年8月至1975年5月)的美国退伍军人。排除人口数据不完整或在随访期间或之前已患有突触核蛋白病的个体。橙剂暴露由自我报告定义,直接职业暴露定义为参与牧场手行动、陆军化学部队以及/或直接处理或喷洒。计算调整了死亡竞争风险、年龄、创伤性脑损伤和衰弱后的突触核蛋白病累积发病率。在筛选4917272名美国退伍军人后,将4468509名退伍军人(平均年龄60.6岁,标准差8;男性4380139名占98%)纳入分析。共有1035210名退伍军人(23.2%)有橙剂暴露史;其中7600名(0.2%)有直接职业暴露史。出生年份、基线年龄、性别、种族、族裔和吸烟史在暴露组与非暴露组间平衡,并进一步调整了创伤性脑损伤和衰弱。橙剂暴露与帕金森病风险增加相关(风险比1.44;95%置信区间1.37-1.52)、快速眼动睡眠行为障碍风险增加(风险比1.78;95%置信区间1.68-1.89)和路易体痴呆风险增加(风险比1.66;95%置信区间1.32-2.09)。在富集直接职业暴露时,关联增强,包括帕金森病(风险比1.99;95%置信区间1.71-2.32)和快速眼动睡眠行为障碍(风险比2.25;95%置信区间1.87-2.70)。结果在进一步调整创伤性脑损伤、衰弱、医疗保健利用率和多重插补后依然稳健。敏感性分析表明,需要大量的未测量混杂因素才能解释观察到的关联。队列研究结果表明,橙剂可能是后续发展为帕金森病及相关疾病的独立危险因素。这一发现对全球政策变革具有启示意义。需要进一步研究以理解该关联的潜在机制、基因-毒素相互作用以及是否存在针对橙剂暴露者的独特临床表型。
基础研究 (3篇)
Parkinson’s disease begins years before motor symptoms appear. Longitudinal blood transcriptomics shows that DNA repair and stress response pathways are most altered during this prodromal phase, then lose discriminative power in established disease. In this Comment, we link these changes to aging-related DNA damage and consider their biomarker potential. Mirroring aging hallmarks, they suggest a prodromal intervention window, when mechanisms driving dopaminergic neuron vulnerability are most active and potentially tractable.
中文摘要:帕金森病的病理过程在运动症状出现前数年即已启动。纵向血液转录组学研究表明,DNA修复和应激反应通路在此前驱阶段发生显著改变,而在疾病确立后其鉴别能力下降。本文评论将这些变化与衰老相关的DNA损伤联系起来,并探讨其作为生物标志物的潜力。这些变化反映了衰老的特征,提示存在一个前驱期干预窗口,此时驱动多巴胺能神经元易感性的机制最为活跃且可能具有可干预性。
Parkinson's disease (PD) is characterized by pathological α-synuclein (α-syn) aggregation arising from dysregulated phase separation, yielding α-syn condensates via liquid-liquid phase separation (LLPS) and α-syn fibrils (α-syn-F) via liquid-solid phase separation (LSPS). It is meaningful to visualize the phase separation of α-syn for in-depth understanding of PD pathology. Herein, an amphiphilic Congo red-derived carbon dot, named as RP-2, was rationally designed. The RP-2 showed turn-on red fluorescence towards α-syn-F rather than monomer, and was utilized as the probe to detect α-syn-F in complex matrices. Besides, the RP-2 could label α-syn condensates without affecting the dynamic characteristics of LLPS, and stain α-syn-F in living cells. Using RP-2 as the staining dye, α-syn condensates were demonstrated to recruit β-synuclein, illustrating that β-synuclein could regulate the α-syn aggregation. Particularly, due to introduction of D-phenylalanine as the carbon source, the RP-2 exhibited enhanced blood-brain barrier (BBB) penetration with the aid of large neutral amino acid transporter 1. Thus, the RP-2 successfully imaged cerebral α-syn-F of A53T mice, and distinguished them from normal ones. The present study offered a feasible method to construct amphiphilic CDs with BBB penetration for visualizing the phase separation of α-syn.
中文摘要:帕金森病的病理特征为α-突触核蛋白因相分离失调而发生聚集,通过液液相分离形成凝聚体,并通过液固相分离形成纤维。可视化α-突触核蛋白的相分离对于深入理解帕金森病病理具有重要意义。本研究合理设计了一种两亲性刚果红衍生碳点RP-2。RP-2对α-突触核蛋白纤维而非单体表现出开启式红色荧光,并被用作探针以在复杂基质中检测α-突触核蛋白纤维。此外,RP-2可在不影响液液相分离动态特征的情况下标记α-突触核蛋白凝聚体,并在活细胞中对α-突触核蛋白纤维进行染色。利用RP-2作为染色染料,证实了α-突触核蛋白凝聚体会招募β-突触核蛋白,表明β-突触核蛋白可调节α-突触核蛋白的聚集。特别地,由于引入D-苯丙氨酸作为碳源,RP-2借助大中性氨基酸转运蛋白1表现出增强的血脑屏障穿透能力。因此,RP-2成功成像了A53T小鼠脑内的α-突触核蛋白纤维,并将其与正常小鼠区分开来。本研究提供了一种构建具有血脑屏障穿透能力的两亲性碳点以可视化α-突触核蛋白相分离的可行方法。
Glycoprotein non-metastatic melanoma protein B (GPNMB), a biomarker of Parkinson's disease (PD), remains at trace levels in clinical samples, which poses a major obstacle for early diagnosis. Herein, a fiber-optic surface plasmon resonance (FO-SPR) sensor based on MOF@Pt-AuPt plasmonic scaffolds is developed for ultrasensitive detection of GPNMB. In-situ growth of Pt nanoparticles on two-dimensional porphyrinic Cu-TCPP MOF forms a Schottky barrier that narrows the optical band gap from 2.53 eV to 2.38 eV, promoting photogenerated charge separation. Subsequent electrostatic assembly of Au@Pt core-shell satellites generates dense localized surface plasmon resonance "hot spots" that strongly couple with the surface plasmon wave on the Au film, and finite-difference time-domain simulations confirm that the interfacial electric field intensity increases from 3.29 to 11.5 (arbitrary units, a.u.). The sensor exhibits excellent refractive index sensing performance, achieving a sensitivity of 3768.64 nm/RIU, which represents a 131.99% improvement over conventional Au-coated optical fibers. For GPNMB detection, the sensor achieves a limit of detection as low as 0.06 pg/mL, more than sevenfold enhancement. Moreover, the sensor is capable of unambiguously discriminating PD patients from healthy controls while exhibiting superior hydrophilicity, antifouling capability, and selectivity. This method provides a practical and versatile detection strategy for the early diagnosis of Parkinson's disease.
中文摘要:糖蛋白非黑色素瘤转移蛋白B(GPNMB)是帕金森病的生物标志物,但其在临床样本中含量极低,给早期诊断带来重大障碍。本研究开发了一种基于MOF@Pt-AuPt等离子体支架的光纤表面等离激元共振传感器,用于GPNMB的超灵敏检测。在二维卟啉Cu-TCPP金属有机框架上原位生长铂纳米颗粒形成肖特基势垒,将光学带隙从2.53 eV缩小至2.38 eV,促进光生电荷分离。随后通过静电组装金@铂核壳卫星结构,产生密集的局域表面等离激元共振热点,与金膜表面的等离激元波强烈耦合,时域有限差分模拟证实界面电场强度从3.29增加至11.5(任意单位)。该传感器表现出优异的折射率传感性能,灵敏度达到3768.64 nm/RIU,较传统镀金光纤提升131.99%。在GPNMB检测中,传感器的检测限低至0.06 pg/mL,提升了七倍以上。此外,该传感器能够明确区分帕金森病患者与健康对照组,并表现出优越的亲水性、抗污染能力和选择性。该方法为帕金森病的早期诊断提供了一种实用且通用的检测策略。
7多发性硬化与神经免疫 (2篇)
临床研究 (2篇)
Multiple sclerosis (MS) is a chronic inflammatory central nervous system (CNS) disease. Although current immunotherapies control relapses, they have limited impact on progression, which might reflect incomplete access to or modulation of compartmentalized CNS inflammation. Chimeric antigen receptor (CAR) T cells can infiltrate tissues, but their ability to access and eliminate immune cells residing in the CNS remains elusive. We report the treatment of five individuals with progressive or relapsing-remitting MS with autologous CD19 CAR T cells to assess safety-relevant aspects, CNS bioavailability, and compartment-specific effects. The intervention induces remodeling of the cerebrospinal fluid (CSF) B cell pool, with a sustained reduction in CSF humoral biomarkers. Notably, CSF-infiltrating CAR T cells selectively upregulate phosphodiesterase 7B, while reconstituted peripheral B cells show altered cytokine and homing profiles. These findings indicate compartment-specific immunomodulation beyond peripheral B cell depletion and support controlled trials to test safety, durability, and efficacy.
中文摘要:多发性硬化(MS)是一种慢性炎症性中枢神经系统疾病。尽管当前的免疫疗法能控制复发,但对疾病进展的影响有限,这可能反映了其对 compartmentalized 中枢神经系统炎症的访问或调节不完整。嵌合抗原受体 T 细胞能够浸润组织,但其进入并清除驻留于中枢神经系统的免疫细胞的能力仍不明确。我们报告了使用自体 CD19 CAR T 细胞治疗五名进展型或复发型缓解型 MS 患者的情况,以评估安全性相关方面、中枢神经系统生物利用度及 compartment-specific 效应。该干预措施诱导脑脊液 B 细胞池的重塑,并持续降低脑脊液中的体液生物标志物。值得注意的是,浸润脑脊液的 CAR T 细胞选择性上调磷酸二酯酶 7B,而重建的外周 B 细胞显示出改变的细胞因子和归巢特征。这些发现表明存在超出外周 B 细胞耗竭的 compartment-specific 免疫调节,并支持开展对照试验以测试其安全性、持久性和疗效。
Clinical progression is strongly linked to gray matter atrophy in multiple sclerosis (MS), detectable early on MRI and progressing nonrandomly across the brain. However, the mechanisms driving its spatiotemporal progression and individual variability remain unclear. Using MRIs from 2187 participants, alongside normative data, we systematically investigated network-based mechanisms underlying MS-related atrophy. Regional atrophy was associated with functional cortical hubness, supporting the nodal stress hypothesis, and was constrained by anatomical and functional connections, consistent with transneuronal degeneration. Lesional disconnection and transcriptomic vulnerability played marginal roles. Patient- and subgroup-level analyses revealed that network-based mechanisms are specifically linked to MS-related neurodegeneration and may operate differently in distinct subtypes or disease phases. Atrophy patterns were anchored to the connectivity profiles of disease epicenters involving the visual, sensorimotor, and temporal cortices, as well as the hippocampi, amygdalae, and thalami. Network-based measures enhanced the explanation of future atrophy progression in people with MS, providing a mechanistic framework to understand neurodegeneration in MS.
中文摘要:临床进展与多发性硬化中的灰质萎缩密切相关,这种萎缩在磁共振成像中可早期检测,并在大脑中非随机地进展。然而,驱动其时空进展和个体差异的机制尚不清楚。我们利用2187名参与者的磁共振成像数据及规范数据,系统研究了基于网络的潜在机制。区域性萎缩与功能皮层枢纽性相关,支持节点应激假说,并受解剖和功能连接的约束,符合神经元间退行性变的特征。病灶断开和转录组脆弱性作用有限。患者及亚组水平分析显示,基于网络的机制与多发性硬化相关的神经退行性变具体相关,且可能在不同亚型或疾病阶段以不同方式运作。萎缩模式锚定于涉及视觉、感觉运动及颞叶皮层以及海马、杏仁核和丘脑的疾病中心区域的连接特征。基于网络的指标增强了多发性硬化患者未来萎缩进展的解释能力,为理解多发性硬化中的神经退行性变提供了机制框架。
8神经重症与脑损伤 (1篇)
基础研究 (1篇)
Recent evidence has suggested that dysfunction of the autophagy-lysosome system was a crucial factor leading to neuronal damage, yet the underlying regulatory mechanisms remain unclear. Studies have reported that Toll like receptor 9 (TLR9) is required for autophagic flux. In our investigation, we observed that TLR9 was significantly upregulated and exerted a protective role through promoting the fusion of autophagosomes and lysosomes in the stroke models. Mechanistically, we found that tripartite motif-containing protein 31 (TRIM31) interacted with TLR9 and promoted the k48-linked polyubiquitination of TLR9, consequently facilitated its degradation in a proteasome-dependent pathway. Furthermore, TRIM31 led to impaired autophagosome-lysosome fusion in cerebral ischemic injury by negatively regulating TLR9. In conclusion, we identified TRIM31 as a novel E3 ubiquitin ligase for TLR9 degradation and provided a new therapeutic strategy to alleviate ischemic brain injury by enhancing autophagosome-lysosome fusion via TLR9.
中文摘要:近期证据表明自噬溶酶体系统功能障碍是导致神经元损伤的关键因素,但其潜在调控机制尚不明确。已有研究报道Toll样受体9(TLR9)是自噬流所必需的。在本研究中,我们观察到在卒中模型中TLR9显著上调并通过促进自噬体与溶酶体融合发挥保护作用。机制上我们发现TRIM31与TLR9相互作用并促进其K48连接的多聚泛素化,从而通过蛋白酶体依赖性途径促进其降解。此外,TRIM31通过负向调控TLR9导致脑缺血损伤中自噬体与溶酶体融合受损。总之,我们确定TRIM31是TLR9降解的新型E3泛素连接酶,并通过增强自噬体与溶酶体融合提供了减轻缺血性脑损伤的新治疗策略。
9头痛与疼痛 (1篇)
临床研究 (1篇)
Eptinezumab is a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) for migraine prevention, offering rapid onset and quarterly intravenous administration. However, evidence regarding patient and healthcare professional (HCP) experiences and its implementation in routine practice remains limited. This study has explored the opportunities and challenges of eptinezumab treatment. This convergent mixed-methods study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. A total of 20 patients with migraine who received eptinezumab and 10 HCPs participated. Monthly headache days (MHDs) and Migraine Disability Assessment (MIDAS) scores were evaluated over 6 months for patients. Semi-structured in-depth interviews explored experiences with eptinezumab treatment for both participant groups, with transcripts analyzed using thematic analysis. Median MHDs decreased from 18.5 (IQR 8.5-28.0) at baseline to 5.0 (2.0-8.0) at Month 3 and 2.5 (1.0-5.0) at Month 6. Median MIDAS scores decreased from 63.5 (30.0-77.5) to 15.0 (1.0-33.0) and 5.0 (0.5-19.5), respectively. Qualitative findings identified three opportunities: improved migraine symptoms and quality of life, favorable treatment experience and acceptability, and addressing unmet needs in patients with migraine who had experienced multiple preventive treatment failures. Patients and HCPs described improved migraine control, restored daily functioning, and favorable tolerability. Three major challenges emerged: financial and access barriers, health-system and service delivery challenges, and treatment-related concerns. High costs and limited reimbursement were the predominant barriers identified by both participant groups. Patients and HCPs perceived eptinezumab as an effective and well-accepted preventive treatment. Although quarterly intravenous administration was viewed favorably, financial barriers and healthcare system constraints remain major obstacles to broader implementation. These findings offer practical insights into integrating CGRP-targeting therapies into routine care. NCT07035197 (ClinicalTrials.gov).
中文摘要:依普奈单抗是一种降钙素基因相关肽单克隆抗体,用于偏头痛预防,具有起效快和每季度静脉给药的特点。然而,关于患者和医疗保健专业人员体验及其在常规实践中应用的证据仍然有限。本研究探讨了依普奈单抗治疗的机会与挑战。这项收敛性混合方法研究在泰国曼谷朱拉隆功纪念医院开展。共有20名接受依普奈单抗治疗的偏头痛患者和10名医疗保健专业人员参与。对患者进行了为期6个月的每月头痛天数和偏头痛残疾评估评分评估。半结构化深度访谈探讨了双方参与者对依普奈单抗治疗的经验,转录稿采用主题分析进行分析。中位每月头痛天数从基线的18.5降至第3个月的5.0和第6个月的2.5。中位偏头痛残疾评估评分分别从63.5降至15.0和5.0。定性研究确定了三个机会:改善偏头痛症状和生活质量、良好的治疗体验和可接受性,以及解决经历过多次预防性治疗失败的偏头痛患者的未满足需求。患者和医疗保健专业人员描述了偏头痛控制改善、日常功能恢复和良好的耐受性。出现了三大主要挑战:财务和准入障碍、卫生系统和医疗服务交付挑战以及与治疗相关的担忧。高成本和有限的报销是双方参与者确定的主要障碍。患者和医疗保健专业人员认为依普奈单抗是一种有效且易于接受的预防性治疗方法。尽管每季度静脉给药受到青睐,但财务障碍和医疗系统限制仍然是更广泛实施的主要障碍。这些发现为将靶向降钙素基因相关肽疗法整合到常规护理中提供了实用见解。